

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

B1

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>5</sup> : C12N 15/12, C12Q 1/68 C12P 21/08, A61K 37/02		A1	(11) International Publication Number: WO 92/05254 (43) International Publication Date: 2 April 1992 (02.04.92)
(21) International Application Number: PCT/US91/06950 (22) International Filing Date: 24 September 1991 (24.09.91)  (30) Priority data: 587,707 25 September 1990 (25.09.90) US 648,482 31 January 1991 (31.01.91) US  (60) Parent Application or Grant (63) Related by: Continuation US 648,482 (C1P) Filed on 31 January 1991 (31.01.91)  (71) Applicant (for all designated States except US): GENENTECH, INC. (US/US); 460 Point San Bruno Boulevard, South San Francisco, CA 94080 (US).		(72) Inventor; and (75) Inventor/Applicant (for US only): ROSENTHAL, Arnon (IL/US); 1064 Glacier Avenue, Pacifica, CA 94044 (US).  (74) Agents: HENSLEY, Max, D. et al.; Genentech, Inc., 460 Point San Bruno Boulevard, South San Francisco, CA 94080 (US).  (81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US.  Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(54) Title: NOVEL NEUROTHROPHIC FACTOR			
(57) Abstract			
<p>A novel polypeptide, designated neurotrophic factor-4 (NT-4), has been identified by PCR amplification of human genomic DNA. Provided herein is nucleic acid encoding NT-4 useful in diagnostics and in the recombinant preparation of NT-4. Also provided herein are nucleic acids encoding naturally occurring amino acid sequence variants of NT-4, designated NT-4β, NT-4γ, and NT-4Δ. The neurotrophic factors of the invention are useful in the treatment of nerve cells and in diagnostic assays.</p>			
NT4	1	.....MLPLPSCSL	
NT4beta	1	.....ERCSEKCSH	
NT4gamma	1	SKGFPIILAGRPPLGFPTSDPTEVFIFFPNPSLLFPVSMCSERCSEKCSG	
NT4	10	PIL.....LFLPSPVPIESOPPPSTLPFLAPEWDLSPRVLSRGAP	
NT4beta	10	SPRLPPHPHPFPPOCVNGVLTSPSTLSPPFPPEWDLFPVLSRGAAA	
NT4gamma	51	SPRLPPHPHPFPPOCVIGVLTSPSTLSRFPPEWDLFPVLSRGAAA	
NT4delta	1	.....PPP.....L.....LSFPPEWDLIFPPVLSRGAAA	
NT4	55	GPPLFLLEAGAFRESAGAPANRSRRGVSETPASRRGELAVCDVSGVW	
NT4beta	60	GPPLVFLLETGAFRESAGARANRSORGVS DTSPASHOGELAVCDVSVWV	
NT4gamma	101	GPPLVFLLETGAFRESAGARANRSORGVS DTSPVSHOGELAVCDVTVWV	
NT4delta	30	GPPLVFLLETGAFRESAGTANRSORGVS DTSPASHOGELAVCDVSVWV	
NT4	105	TDRRTAVDILRGREVEVLGEVPAAGGSPLRQYFFETRICADNAEEGGPGAG	
NT4beta	170	TDPWTAVDLGVLEVEVLGEVPAAGVGSLLRQHFFVIRFEADKSEEGPGVG	
NT4gamma	151	TDPWTAVDLGVLEVEVLGEVPAAGSSSLRQHFFVTRFEADKSEEGPGVG	
NT4delta	80	TDPRTAVDILVLEVEVLGEVPAAGSSSLRQHFFVTCFKADNSEEGPGVG	
NT4	155	GGGCRGVDRRHVVSECKAKOSYVRALTADAQGRVGRWIRITACVCTL	
NT4beta	160	GGAAAGVWTGGHVVSECKAKOSYVRALTADAQGRVDWRWIOIGTACVCTL	
NT4gamma	201	GGPAAGVWTGGHVVSECKAKOSYGRALTIDAQGRVDWRWIOIGTACVCTL	
NT4delta	130	GGAAAGVWTGGHVVSECKAKOSYVRALTADAQGRVDWRWIOGTACVCTL	
NT4	204	LSRTGRA	
NT4beta	210	LSRTGRA	
NT4gamma	251	LSRTGRA	
NT4delta	190	LSRTGRA	

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU <sup>+</sup>	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE*	Germany	MC	Monaco	US	United States of America
DK	Denmark				

<sup>+</sup> Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

## NOVEL NEUROTROPHIC FACTOR

Field of the Invention

This application relates to proteins which are involved in the growth, regulation or maintenance of nervous tissue. In particular, it relates to a nerve-derived factors having  
5 homology to NGF.

Background of the Invention

Nerve growth factor (NGF) is a protein which has prominent effects on developing sensory and sympathetic neurons of the peripheral nervous system. NGF acts via specific cell surface receptors on responsive neurons to support neuronal survival, promote neurite  
10 outgrowth, and enhance neurochemical differentiation. NGF actions are accompanied by alterations in neuronal membranes (Connolly et al., 1981, J. Cell. Biol. 90:176; Skaper and Varon, 1980, Brain Res. 197:379), in the state of phosphorylation of neuronal proteins (Yu, et al., 1980, J. Biol. Chem. 255:10481; Haleqoua and Patrick, 1980, Cell 22:571), and in the abundance of certain mRNAs and proteins likely to play a role in neuronal differentiation  
15 and function (Tiercy and Shooter, 1986, J. Cell. Biol. 103:2367).

Forebrain cholinergic neurons also respond to NGF and may require NGF for trophic support. (Hefti, 1986, J. Neurosci., 6:2155). Indeed, the distribution and ontogenesis of NGF and its receptor in the central nervous system (CNS) suggest that NGF acts as a target-derived neurotrophic factor for basal forebrain cholinergic neurons (Korsching, Nov/Dec 1986,  
20 Trends in Neuro. Sci., pp 570-573).

While a number of animal homologues to NGF have become known, it was not until recently that an apparently distinct nerve growth factor was identified that nonetheless bears some homology to NGF (Leibrock et al., 1989, Nature 341:149). This factor, called brain-derived neurotrophic factor (BDNF), now also called NT-2, was purified from pig brain, and  
25 a partial amino acid sequence determined both from the N-terminal end and from fragments purified after cleavages. The longest sequence, compiled from several overlapping fragments, was used to synthesize two sets of oligonucleotides that were used to prime the amplification of a pig genomic template using the polymerase chain reaction (PCR). The nucleotide sequence between the two primers was determined and used to synthesize specific primers  
30 for further PCRs on a complementary DNA template obtained by reverse transcription of total RNA isolated from the superior colliculus of the pig brain. The nucleotide sequence so obtained contained an open reading frame coding for a protein of 252 amino acids, starting with the first methionine codon found after four in-frame stop codons. Leibrock, et al. speculate that there is no reason to think that BDNF and NGF should be the only members  
35 of a family of neurotrophic proteins having in common structural and functional characteristics, and the authors hope that these common structural features could be used to aid the discovery of other members.

More recently, another novel neurotrophic factor closely related to  $\beta$ NGF and BDNF was discovered, called neuronal factor (NF), or neurotrophin-3 (NT-3). (Hohn, et al., 1990, Nature 344:339; Maisonpierre, et al., 1990, Science 247:1446; Rosenthal, et al., 1990, Neuron 4:767. Both BDNF and NT-3 share approximately 50% of their amino acids with  $\beta$ NGF. High levels of mRNA coding for BDNF and NT-3 occur in the adult rodent brain.  $\beta$ NGF, BDNF, and NT-3 support survival of selected populations of chick sensory neurons, suggesting independent roles in the regulation of neuronal survival during development.

Neuronal survival and growth is also affected by growth factors for non-neuronal cells, including fibroblast growth factor (FGF), epidermal growth factor, and insulin-like growth factors. (Morrison, et al., 1987, Science 238:72; Walicke, 1988, J. Neurosci. 8:2618; Bhat, 1983, Dev. Brain Res. 11:315). Basic FGF (bFGF) supports initial survival and subsequent fiber outgrowth of dissociated rodent fetal neurons in culture. While neurons from many brain regions are affected, the proportion of neurons surviving varies among brain regions, suggesting that subpopulations of neurons are responsive to bFGF. (Morrison, et al., 1986, Proc. Natl. Acad. Sci. 83:7537; Walicke, et al., 1986, Proc. Natl. Acad. Sci. USA 83:3012). Since bFGF lacks a signal sequence typical for released proteins, and since bFGF levels present in the brain are much larger than those of  $\beta$ NGF and BDNF, it has been questioned whether bFGF plays a physiological role as neurotrophic factor and has been proposed that bFGF acts as "injury factor" released in events involving cellular destruction. (Thoenen, et al., 1987, Rev. Physiol. Biochem. Pharmacol. 109:145).

Another neurotrophic factor having potential therapeutic use for peripheral nervous system disorders, ciliary neurotrophic factor (CNTF), has been cloned and expressed. (Lin, et al., 1989, Science, 246:1023). CNTF, which was purified from adult rabbit sciatic nerves, acts on the peripheral nervous system and appears to be completely unrelated to NGF.

It is an object to identify a fourth neurotrophic factor in the NGF family and to obtain nucleic acid encoding such a factor.

It is another object to synthesize such a new factor in recombinant cell culture.

It is yet another object to provide variants and modified forms of such a new factor.

It is an additional object to prepare immunogens for raising antibodies, as well as to obtain antibodies, capable of binding such a new factor or variant or modified form thereof.

Another object is to provide diagnostic and therapeutic compositions comprising such a new factor or variant or modified forms thereof, and methods of therapeutic treatment.

#### Summary of the Invention

These and other objects of the invention apparent to the ordinary artisan are accomplished by first providing a nucleic acid sequence comprising at least a portion of the coding sequence for a new nerve-derived factor related to NGF, BDNF, and NT-3, hereafter termed neurotrophic factor-4 (NT-4).

In one aspect, the invention provides an isolated nucleic acid encoding NT-4. In another aspect, the invention provides a vector comprising this nucleic acid. In a third



aspect, the invention supplies a recombinant host cell comprising this nucleic acid. In yet another aspect, the invention furnishes a composition comprising NT-4 from an animal species, which composition is free of contaminating polypeptides of that animal species.

5 The nucleic acid encoding NT-4 is also used in hybridization assays to identify and to isolate nucleic acids having substantial sequence homology to the nucleic acid encoding NT-4.

NT-4 or fragments thereof (which also may be synthesized by in vitro methods) are fused (by recombinant expression or in vitro covalent methods) to an immunogenic polypeptide and this, in turn, is used to immunize an animal in order to raise antibodies against an NT-4 epitope. Anti-NT-4 is recovered from the serum of immunized animals.  
10 Alternatively, monoclonal antibodies are prepared from cells of the immunized animal in conventional fashion. Antibodies identified by routine screening will bind to NT-4 but will not substantially cross-react with NGF, BDNF, or NT-3. Immobilized anti-NT-4 antibodies are useful particularly in the diagnosis (in vitro or in vivo) or purification of NT-4.

Substitutional, deletional, or insertional mutants of NT-4 are prepared by in vitro or  
15 recombinant methods and screened for immuno-crossreactivity with NT-4 and for NT-4 antagonist or agonist activity.

NT-4 also is derivatized in vitro in order to prepare immobilized NT-4 and labelled NT-4, particularly for purposes of diagnosis of NT-4 or its antibodies, or for affinity purification of NT-4 antibodies.

20 NT-4, or a variant or modified form thereof, or anti-NT-4 antibody is formulated into physiologically acceptable vehicles, especially for therapeutic use. Such vehicles include sustained-release formulations.

In another aspect, the invention provides a method for producing NT-4, or a variant or modified form thereof, comprising culturing a transformed host cell and recovering the desired  
25 polypeptide from the host cell culture.

NT-4 has been found to have a broad tissue distribution and is structurally related to NGF, BDNF, and NT-3. Its presence in the brain and muscle tissue indicates that it may be useful as a therapeutic agent for neurodegenerative diseases and damaged nerve cells, e.g., nerves damaged as a result of trauma.

30 Therefore, in another aspect, the invention provides a method for treating a neurodegenerative disease or damaged nerve cells comprising administering to a mammal an effective amount of NT-4, or a variant or modified form thereof.

#### Brief Description of the Drawings

Figure 1 shows the partial nucleotide sequence for the human NT-4 gene (SEQ ID NO. 1) and the deduced amino acid sequence (SEQ ID NO. 2), including the entire nucleotide and  
35 amino acid sequences for mature human NT-4. The arrow indicates where the mature sequence begins, the asterisk indicates where the sequence begins for calculating homology with other members of the neurotrophic factor family, and the stop codon is circled. The amino acids are numbered from the N-terminus of the mature region.

Figure 2 shows the homologies among the amino acid sequences of human NT-2 (SEQ ID NO. 3), NT-3 (SEQ ID NO. 4), and NGF (SEQ ID NO. 5), and the mature and partial precursor portion of NT-4 (SEQ ID NO. 6). The locations of the sense (NGX-54) and antisense (AR1) primer sites on the sequence are marked with vertical solid arrows, and the start of the mature region is indicated with an arrow.

Figure 3 shows the nucleotide sequence of a cDNA encoding a portion of human NT-4 $\beta$  (SEQ ID NO. 7), and the deduced amino acid sequence of this portion of NT-4 $\beta$  (SEQ ID NO. 8).

Figure 4 shows the nucleotide sequence of a genomic DNA encoding human NT-4 $\gamma$  (SEQ ID NO. 9), and the deduced amino acid sequence (SEQ ID NO. 10). The first in-frame Met residue is located at nucleotide positions 356-358, and is the putative start codon of human NT-4 $\gamma$ .

Figure 5 shows the nucleotide sequence of a genomic DNA encoding human NT-4 $\Delta$  (SEQ ID NO. 11), and the deduced amino acid sequence of this portion of NT-4 $\Delta$  (SEQ ID NO. 12).

Figure 6 shows the homologies among the amino acid sequences of human NT-4, NT-4 $\beta$ , NT-4 $\gamma$ , and NT-4 $\Delta$ . The arrow indicates where the sequence of mature human NT-4 begins.

#### Detailed Description of the Preferred Embodiments

As used herein, "NT-4" refers to a polypeptide having the amino acid sequence shown in Figure 1 for mature human NT-4, amino acid sequence variants of such polypeptide, peptide fragments of mature human NT-4 and said amino acid sequence variants, which peptides are at least about 5 amino acids in length and comprise an immune epitope or other biologically active site of the corresponding polypeptide, and modified forms of mature human NT-4 and said amino acid sequence variants and peptide fragments wherein the polypeptide or peptide has been covalently modified by substitution with a moiety other than a naturally occurring amino acid; provided, however, that the particular amino acid sequence variant, peptide fragment, or modified form thereof under consideration is novel and unobvious over the prior art, and is not NGF, BDNF, or NT-3 of any animal species or any fragment or modified form of such NGF, BDNF, or NT-3.

NT-4 nucleic acid is RNA or DNA which encodes a NT-4 polypeptide or which hybridizes to such DNA and remains stably bound to it under stringent conditions and is greater than about 10 bases in length; provided, however, that such hybridizing nucleic acid is novel and unobvious over any prior art nucleic acid including that which encodes or is complementary to nucleic acid encoding NGF, BDNF, or NT-3. Stringent conditions are those which (1) employ low ionic strength and high temperature for washing, for example, 0.15 M NaCl / 0.015 M sodium citrate / 0.1% NaDodSO<sub>4</sub> at 50°C, or (2) use during hybridization a denaturing agent such as formamide, for example, 50% (vol/vol) formamide with 0.1%

bovine serum albumin/0.1% Ficoll / 0.1% polyvinylpyrrolidone / 50 mM sodium phosphate buffer at pH 6.5 with 750 mM NaCl, 75 mM sodium citrate at 42°C.

DNA encoding NT-4 is obtained from brain tissue cDNA libraries, or genomic DNA, or by in vitro synthesis. Hybridizing nucleic acid generally is obtained by in vitro synthesis.

- 5 Identification of NT-4 DNA most conveniently is accomplished by probing human cDNA or genomic libraries by labeled oligonucleotide sequences selected from the Figure 1 sequence in accord with known criteria, among which is that the sequence should be of sufficient length and sufficiently unambiguous that false positives are minimized. Typically, a <sup>32</sup>P-labeled oligonucleotide having about 30 to 50 bases is sufficient, particularly if the
- 10 oligonucleotide contains one or more codons for methionine or tryptophan. Isolated nucleic acid will be DNA that is identified and separated from contaminant nucleic acid encoding other polypeptides from the source of nucleic acid. The nucleic acid may be labeled for diagnostic purposes.

- Amino acid sequence variants of NT-4 are polypeptides having an amino acid sequence
- 15 which differs from that shown in Figure 1 for mature human NT-4 by virtue of the insertion, deletion, and/or substitution of one or more amino acid residues within the Figure 1 sequence. Amino acid sequence variants generally will be about 75% homologous (and often greater than 85% homologous) to mature human NT-4 based on a comparison of the amino acids present at each position within the sequences, after aligning the sequences to provide for
- 20 maximum homology.

- Amino acid sequence variants of NT-4 may be naturally occurring or may be prepared synthetically, such as by introducing appropriate nucleotide changes into a previously isolated NT-4 DNA, or by in vitro synthesis of the desired variant polypeptide. As indicated above, such variants will comprise deletions from, or insertions or substitutions of, one or more
- 25 amino acid residues within the amino acid sequence shown for mature human NT-4 in Figure 1. Any combination of deletion, insertion, and substitution is made to arrive at an amino acid sequence variant of NT-4, provided that the resulting variant polypeptide possesses a desired characteristic. The amino acid changes also may result in further modifications of NT-4 upon expression in recombinant hosts, e.g. introducing or moving sites of glycosylation, or
- 30 introducing membrane anchor sequences (in accordance with PCT WO 89/01041 published Feb. 9, 1989).

- Preferably, an amino acid sequence variant of NT-4 that is naturally occurring, including, for example, a naturally occurring allele, will be produced by recombinant means by expressing in a suitable host cell genomic DNA or cDNA comprising the nucleotide coding
- 35 sequence for such naturally occurring variant. Other amino acid sequence variants of NT-4 will be produced by making predetermined mutations in a previously isolated NT-4 DNA. There are two principal variables to consider in making such predetermined mutations: the location of the mutation site and the nature of the mutation. In general, the location and nature of the mutation chosen will depend upon the NT-4 characteristic to be modified. For

-6-

example, candidate NT-4 antagonists or super agonists initially will be selected by locating amino acid residues that are identical or highly conserved among NGF, BDNF, NT-3, and NT-4. Those residues then will be modified in series, e.g., by (1) substituting first with conservative choices and then with more radical selections depending upon the results achieved, (2) deleting the target residue, or (3) inserting residues of the same or different class adjacent to the located site, or combinations of options 1-3.

One helpful technique is called "ala scanning". Here, an amino acid residue or group of target residues are identified and substituted by alanine or polyalanine. Those domains demonstrating functional sensitivity to the alanine substitutions then are refined by introducing further or other variants at or for the sites of alanine substitution.

Obviously, such variations which, for example, convert NT-4 into NGF, BDNF, or NT-3 are not included within the scope of this invention, nor are any other NT-4 variants or polypeptide sequences that are not novel and unobvious over the prior art. Thus, while the site for introducing an amino acid sequence variation is predetermined, the nature of the mutation per se need not be predetermined. For example, to optimize the performance of a mutation at a given site, ala scanning or random mutagenesis is conducted at the target codon or region and the expressed NT-4 variants are screened for the optimal combination of desired activity.

Amino acid sequence deletions generally range from about 1 to 30 residues, more preferably about 1 to 10 residues, and typically are contiguous. Deletions may be introduced into regions of low homology among BDNF, NGF, NT-3, and NT-4 to modify the activity of NT-4. Deletions from NT-4 in areas of substantial homology with BDNF, NT-3, and NGF will be more likely to modify the biological activity of NT-4 more significantly. The number of consecutive deletions will be selected so as to preserve the tertiary structure of NT-4 in the affected domain, e.g., beta-pleated sheet or alpha helix.

Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a thousand or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Intrasequence insertions (i.e., insertions within the mature NT-4 sequence) may range generally from about 1 to 10 residues, more preferably 1 to 5, most preferably 1 to 3. An example of a terminal insertion includes fusion of a heterologous N-terminal signal sequence to the N-terminus of the NT-4 molecule to facilitate the secretion of mature NT-4 from recombinant hosts. Such signals generally will be homologous to the intended host cell and include STII or lpp for *E. coli*, alpha factor for yeast, and viral signals such as herpes gD for mammalian cells. Other insertions include the fusion of an immunogenic polypeptide such as a bacterial or yeast protein to the N- or C-termini of NT-4.

The third group of variants are those in which at least one amino acid residue in NT-4, and preferably only one, has been removed and a different residue inserted in its place. An example is the replacement of arginine and lysine by other amino acids to render the NT-4

-7-

resistent to proteolysis by serine proteases, thereby creating a variant of NT-4 that is more stable. The sites of greatest interest for substitutional mutagenesis include sites where the amino acids found in BDNF, NGF, NT-3, and NT-4 are substantially different in terms of side chain bulk, charge or hydrophobicity, but where there also is a high degree of homology at the selected site within various animal analogues of NGF, NT-3, and BDNF (e.g., among all the animal NGFs, all the animal NT-3s, and all the BDNFs). This analysis will highlight residues that may be involved in the differentiation of activity of the trophic factors, and therefore, variants at these sites may affect such activities. Examples of such sites in mature human NT-4, numbered from the N-terminal end, and exemplary substitutions include NT-4 (G78-->K, H, Q or R) (SEQ ID NOS. 13, 14, 15, and 16, respectively) and NT-4 (R85-->E, F, P, Y or W) (SEQ ID NOS. 17, 18, 19, 20, and 21, respectively). Other sites of interest are those in which the residues are identical among all animal species' BDNF, NGF, NT-3, and NT-4, this degree of conformation suggesting importance in achieving biological activity common to all four factors. These sites, especially those falling within a sequence of at least 3 other identically conserved sites, are substituted in a relatively conservative manner. Such conservative substitutions are shown in Table 1 under the heading of preferred substitutions. If such substitutions result in a change in biological activity, then more substantial changes, denominated exemplary substitutions in Table 1, or as further described below in reference to amino acid classes, are introduced and the products screened.

20

Table 1

Original Residue	Exemplary <u>Substitutions</u>	Preferred <u>Substitutions</u>
Ala (A)	val; leu; ile	val
Arg (R)	lys; gln; asn	lys
25 Asn (N)	gln; his; lys; arg	gln
Asp (D)	glu	glu
Cys (C)	ser	ser
Gln (Q)	asn	asn
Glu (E)	asp	asp
30 Gly (G)	pro	pro
His (H)	asn; gln; lys; arg;	arg
Ile (I)	leu; val; met; ala; phe; norleucine	leu
Leu (L)	norleucine; ile; val; met; ala; phe	ile
35 Lys (K)	arg; gln; asn	arg
Met (M)	leu; phe; ile	leu
Phe (F)	leu; val; ile; ala	leu
Pro (P)	gly	gly

-8-

	Ser (S)	thr	thr
	Thr (T)	ser	ser
	Trp (W)	tyr	tyr
	Tyr (Y)	trp; phe; thr; ser	phe
5	Val (V)	ile; leu; met; phe; ala; norleucine	leu

Sites particularly suited for conservative substitutions include, numbered from the N-terminus of the mature human NT-4, R11, G12, E13, V16, D18, W23, V24, D26, V40, L41, Q54, Y55, F56, E58, T59, G77, R79, G80, H85, W86, A99, L100, T101, W110, R111, W112, I113, R114, I115, D116, and A118. Cysteine residues not involved in maintaining the proper conformation of NT-4 also may be substituted, generally with serine, in order to improve the oxidative stability of the molecule and prevent aberrant crosslinking. Sites other than those set forth in this paragraph are suitable for deletional or insertional studies generally described above.

Substantial modifications in function or immunological identity are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Naturally occurring residues are divided into groups based on common side chain properties:

- (1) hydrophobic: norleucine, met, ala, val, leu, ile;
- (2) neutral hydrophilic: cys, ser, thr;
- (3) acidic: asp, glu;
- (4) basic: asn, gln, his, lys, arg;
- (5) residues that influence chain orientation: gly, pro; and
- (6) aromatic: trp, tyr, phe.

Non-conservative substitutions will entail exchanging a member of one of these classes for another. Such substituted residues also may be introduced into the conservative substitution sites set forth above or, more preferably, into the remaining (non-conserved) sites.

Examples of NT-4 variants include NT-4(E67-->S or T) (SEQ ID NOS. 22 and 23, respectively) (this adds an N-linked glycosylation site); NT-4(R83-Q94) (SEQ ID NO. 24); NT-4(G1-C61) (SEQ ID NO. 25) (variants so depicted are fragments containing the residues indicated); NT-4(G1-C17) (SEQ ID NO. 26); NT-4(C17-C61) (SEQ ID NO. 27); NT-4(C17-C78) (SEQ ID NO. 28); NT-4(C17-C90) (SEQ ID NO. 29); NT-4(C17-C119) (SEQ ID NO. 30); NT-4(C17-C121) (SEQ ID NO. 31); NT-4(R11-R27) (SEQ ID NO. 32); NT-4(R11-R34) (SEQ ID NO. 33); NT-4(R34-R53) (SEQ ID NO. 34); NT-4(C61-C78) (SEQ ID NO. 35); NT-4(R53-C61) (SEQ ID NO. 36); NT-4(C61-C119) (SEQ ID NO. 37); NT-4(C61-C78) (SEQ ID NO. 38); NT-4(C78-C119) (SEQ ID NO. 39); NT-4(C61-C90) (SEQ ID NO. 40); NT-4(R60-C78) (SEQ ID NO. 41);

NT-4(K62-C119) (SEQ ID NO. 42); NT-4(K62-K91) (SEQ ID NO. 43); NT-4(R79-R98) (SEQ ID NO. 44); NT-4(R83-K93) (SEQ ID NO. 45); NT-4(T101-R111) (SEQ ID NO. 46); NT-4(G1-C121) V L T V K R V R R (SEQ ID NO. 47); NT-4(V40-C121) V L T V K R V R R (SEQ ID NO. 48); NT-4(V40-C121) S L T I K R I R A (SEQ ID NO. 49); NT-4(V40-C121) T L S R K A G R R A (SEQ ID NO. 50); D D D S P I A R R G E I S V C D S V S D W V S A P D K D T A V D I K G D D V M V L K K V G I N H S V NT-4(V40-C121) (SEQ ID NO. 51); hNGF(S1-V48) NT-4(V40-C121) hNGF(V109-A120) (SEQ ID NO. 52); NT-4( $\Delta$ C78) (SEQ ID NO. 53); NT-4( $\Delta$ C61) (SEQ ID NO. 54); NT-4( $\Delta$ O54- $\Delta$ T59) (SEQ ID NO. 55) (variants depicted in this fashion comprise deletions of the indicated span of residues, inclusive); NT-4( $\Delta$ R60- $\Delta$ D82) (SEQ ID NO. 56); NT-4( $\Delta$ H85- $\Delta$ S88) (SEQ ID NO. 57); NT-4( $\Delta$ W86- $\Delta$ T101) (SEQ ID NO. 58); NT-4(R53-->H) (SEQ ID NO. 59); NT-4(K91-->H) (SEQ ID NO. 60); NT-4(V108-->F) (SEQ ID NO. 61); NT-4(R84-->Q, H, N, T, Y or W) (SEQ ID NOS. 62, 63, 64, 65, 66, and 67, respectively); and NT-4(D116-->E, N, Q, Y, S or T) (SEQ ID NOS. 68, 69, 70, 71, 72, and 73, respectively).

Also included is NT-4 wherein position 70 is substituted with an amino acid residue other than G, E, D or P; position 71 with other than A, P or M; and/or position 83 with other than R, D, S or K; as well as cyclized NT-4 fragments, including cyclic polypeptides comprising the sequences IKTG (SEQ ID NO. 74), EIKTG (SEQ ID NO. 75), EIKTGN (SEQ ID NO. 76), SPV, SPVK (SEQ ID NO. 77), HQV, KSS, KSSA (SEQ ID NO. 78), YAEHKS (SEQ ID NO. 79), RYAEHKS (SEQ ID NO. 80), RYAEHKSH (SEQ ID NO. 81), YAEHKSH (SEQ ID NO. 82), ANRTS (SEQ ID NO. 83), NRT, ANRT (SEQ ID NO. 84), NRTS (SEQ ID NO. 85), KEA, KEAR (SEQ ID NO. 86), KEARP (SEQ ID NO. 87), IDDK (SEQ ID NO. 88), SENN (SEQ ID NO. 89), TSENN (SEQ ID NO. 90), TSENNK (SEQ ID NO. 91) or KLVG (SEQ ID NO. 92).

Also within the scope hereof are BDNF, NT-3, and NGF amino acid sequence variants having analogous structures to the NT-4 variants set forth herein. For example, the analogous positions of NGF, NT-3, and BDNF are substituted with a residue other than D, E, or P, respectively, in analogy to the same mutation at position 70 of NT-4.

DNA encoding amino acid sequence variants of NT-4 may be isolated from a natural source (in the case of naturally occurring amino acid sequence variants) or may be prepared by site-specific mutagenesis of DNA that encodes an earlier prepared variant or a nonvariant version of NT-4. Site-specific mutagenesis allows the production of NT-4 variants through the use of specific oligonucleotide sequences that encode the DNA sequence of the desired mutation, as well as a sufficient number of adjacent nucleotides, to provide a primer sequence of sufficient size and sequence complexity to form a stable duplex on both sides of the deletion junction being traversed. Typically, a primer of about 20 to 25 nucleotides in length is preferred, with about 5 to 10 residues on both sides of the junction of the sequence being altered. In general, the technique of site-specific mutagenesis is well known in the art, as exemplified by publications such as Adelman, et al., 1983, DNA 2:183.

As will be appreciated, the site-specific mutagenesis technique typically employs a phage vector that exists in both a single-stranded and double-stranded form. Typical vectors useful in site-directed mutagenesis include vectors such as the M13 phage, for example, as disclosed by Messing, et al., 1981, Third Cleveland Symposium on Macromolecules and Recombinant DNA, (A. Walton, Ed., Elsevier, Amsterdam). These phage are readily commercially available and their use is generally well known to those skilled in the art. Also, plasmid vectors that contain a single-stranded phage origin of replication (Veira, et al., 1987, Meth. Enzymol. 153:3) may be employed to obtain single-stranded DNA. Alternatively, nucleotide substitutions are introduced by synthesizing the appropriate DNA fragment in vitro and amplifying it by polymerase chain reaction (PCR) procedures known per se in the art.

In general, site-directed mutagenesis in accordance herewith is performed by first obtaining a single-stranded vector that includes within its sequence a DNA sequence that encodes the relevant protein. An oligonucleotide primer bearing the desired mutated sequence is prepared, generally synthetically, for example, by the method of Crea, et al., 1978, Proc. Natl. Acad. Sci. 75:5765). This primer is then annealed with the single-stranded protein-sequence-containing vector, and subjected to DNA-polymerizing enzymes such as E. coli polymerase I Klenow fragment, to complete the synthesis of the mutation-bearing strand. Thus, a heteroduplex is formed wherein one strand encodes the original non-mutated sequence and the second strand bears the desired mutation. This heteroduplex vector is then used to transform appropriate cells such as JM101 cells and clones are selected that include recombinant vectors bearing the mutated sequence arrangement.

After such a clone is selected, the mutated region may be removed and placed in an appropriate vector for protein production, generally an expression vector of the type that is typically employed for transformation of an appropriate host.

Most deletions and insertions, and substitutions in particular, of amino acids in NT-4 are not expected to produce radical changes in its characteristics, and single substitutions will preserve at least one immune epitope in the NT-4 polypeptide.

Since it is often difficult to predict in advance the characteristics of a variant NT-4, it will be appreciated that some screening will be needed to identify a variant having a desired characteristic. One can screen for enhanced trophic activity, differential neuron cell type specificity, stability in recombinant cell culture or in plasma (e.g. against proteolytic cleavage), possession of antagonist activity, oxidative stability, ability to be secreted in elevated yields, and the like. For example, a change in the immunological character of the NT-4 polypeptide, such as affinity for a given antibody, is measured by a competitive-type immunoassay. Changes in the enhancement or suppression of neurotrophic activities by the candidate mutants are measured by dendrite outgrowth or explant cell survival assays. Modifications of such protein properties as redox or thermal stability, hydrophobicity, susceptibility to proteolytic degradation, or the tendency to aggregate with carriers or into multimers are assayed by methods well known in the art.



Trypsin or other protease cleavage sites are identified by inspection of the encoded amino acid sequence for paired basic amino acid residues, e.g. combinations of adjacent arginyl and lysinyl residues. These are rendered inactive to protease by substituting one of the residues with another residue, preferably a basic residue such as glutamine or a hydrophobic residue such as serine; by deleting one or both of the basic residues; by inserting a prolyl residue immediately after the last basic residue; or by inserting another residue between the two basic residues.

An amino acid sequence variant of NT-4 typically is produced by recombinant means, that is, by expression of nucleic acid encoding the variant NT-4 in recombinant cell culture, and, optionally, purification of the variant polypeptide from the cell culture, for example, by bioassay of the variant's activity or by adsorption on an immunoaffinity column comprising rabbit anti-NT-4 polyclonal antibodies (which will bind to at least one immune epitope of the variant which is also present in native NT-4). Small peptide fragments, on the order of 40 residues or less, are conveniently made by in vitro methods.

Once DNA encoding NT-4 is obtained, typically it is then ligated into a replicable vector for further cloning or for expression. Vectors are useful for performing two functions in collaboration with compatible host cells (a host-vector system). One function is to facilitate the cloning of the DNA that encodes the NT-4, i.e., to produce usable quantities of the nucleic acid. The other function is to direct the expression of NT-4. One or both of these functions are performed by the vector-host system. The vectors will contain different components depending upon the function they are to perform as well as the host cell that is selected for cloning or expression.

Each vector will contain DNA that encodes NT-4 as described above. Typically, this will be DNA that encodes the NT-4 in its mature form linked at its amino terminus to a secretion signal. This secretion signal preferably is the NT-4 presequence that normally directs the secretion of NT-4 from human cells in vivo. However, suitable secretion signals also include signals from other animal NT-4, signals from NGF, NT-2, or NT-3, viral signals, or signals from secreted polypeptides of the same or related species.

If the signal sequence is from another neurotrophic polypeptide, it may be the precursor sequence shown in Figure 2 which extends from the initiating methionine (M) residue of NT-2, NT-3, or NGF up to the arginine (R) residue just before the first amino acid of the mature protein, or a consensus or combination sequence from any two or more of those precursors taking into account homologous regions of the precursors. The DNA for such precursor region is ligated in reading frame to DNA encoding the mature NT-4.

Expression and cloning vectors contain a nucleotide sequence that enables the vector to replicate in one or more selected host cells. Generally, in cloning vectors this sequence is one that enables the vector to replicate independently of the host chromosomes, and includes origins of replication or autonomously replicating sequences. Such sequences are well-known for a variety of bacteria, yeast and viruses. The origin of replication from the

-12-

well-known plasmid pBR322 is suitable for most gram negative bacteria, the 2 $\mu$  plasmid origin for yeast and various viral origins (SV40, polyoma, adenovirus, VSV or BPV) are useful for cloning vectors in mammalian cells. Origins are not needed for mammalian expression vectors (the SV40 origin may typically be used only because it contains the early promoter). Most expression vectors are "shuttle" vectors, i.e. they are capable of replication in at least one class of organisms but can be transfected into another organism for expression. For example, a vector is cloned in E. coli and then the same vector is transfected into yeast or mammalian cells for expression even though it is not capable of replicating independently of the host cell chromosome.

DNA also is cloned by insertion into the host genome. This is readily accomplished with bacillus species, for example, by including in the vector a DNA sequence that is complementary to a sequence found in bacillus genomic DNA. Transfection of bacillus with this vector results in homologous recombination with the genome and insertion of NT-4 DNA. However, the recovery of genomic DNA encoding NT-4 is more complex than that of an exogenously replicated vector because restriction enzyme digestion is required to excise the NT-4 DNA.

Expression and cloning vectors should contain a selection gene, also termed a selectable marker. Typically, this is a gene that encodes a protein necessary for the survival or growth of a host cell transformed with the vector. The presence of this gene ensures that any host cell which deletes the vector will not obtain an advantage in growth or reproduction over transformed hosts. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g. ampicillin, neomycin, methotrexate or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g. the gene encoding D-alanine racemase for bacilli.

A suitable selection gene for use in yeast is the trp1 gene present in the yeast plasmid YRp7 (Stinchcomb, et al., 1979, Nature 282:39; Kingsman, et al., 1979, Gene 7:141; Tschemper, et al., 1980, Gene 10:157). The trp1 gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No. 44076 or PEP4-1 (Jones, 1977, Genetics 85:12). The presence of the trp1 lesion in the yeast host cell genome then provides an effective environment for detecting transformation by growth in the absence of tryptophan. Similarly, Leu2 deficient yeast strains (ATCC 20,622 or 38,626) are complemented by known plasmids bearing the Leu2 gene.

Examples of suitable selectable markers for mammalian cells are dihydrofolate reductase (DHFR) or thymidine kinase. Such markers enable the identification of cells which were competent to take up the NT-4 nucleic acid. The mammalian cell transformants are placed under selection pressure which only the transformants are uniquely adapted to survive by virtue of having taken up the marker. Selection pressure is imposed by culturing the transformants under conditions in which the concentration of selection agent in the medium is successively changed, thereby leading to amplification of both the selection gene and the

DNA that encodes NT-4. Amplification is the process by which genes in greater demand for the production of a protein critical for growth are reiterated in tandem within the chromosomes of successive generations of recombinant cells. Increased quantities of NT-4 are synthesized from the amplified DNA.

5 For example, cells transformed with the DHFR selection gene are first identified by culturing all of the transformants in a culture medium which contains methotrexate (Mtx), a competitive antagonist of DHFR. An appropriate host cell in this case is the Chinese hamster ovary (CHO) cell line deficient in DHFR activity, prepared and propagated as described by Urlaub and Chasin, 1980, *Proc. Nat. Acad. Sci.* 77:4216. A particularly useful DHFR is a  
10 mutant DHFR that is highly resistant to Mtx (EP 117,060A). The transformed cells then are exposed to increased levels of Mtx. This leads to the synthesis of multiple copies of the DHFR gene and, concomitantly, multiple copies of other DNA comprising the expression vectors, such as the DNA encoding NT-4. Alternatively, host cells transformed by an expression vector comprising DNA sequences encoding NT-4, DHFR protein, and  
15 aminoglycoside 3' phosphotransferase (APH) can be selected by cell growth in medium containing an aminoglycosidic antibiotic such as kanamycin or neomycin or G418. Because eukaryotic cells do not normally express an endogenous APH activity, genes encoding APH protein, commonly referred to as neo<sup>r</sup> genes, may be used as dominant selectable markers in a wide range of eukaryotic host cells, by which cells transformed by the vector can readily  
20 be identified.

Other methods, vectors and host cells suitable for adaptation to the synthesis of NT-4 in recombinant vertebrate cell culture are described in Gething, et al., 1981, *Nature* 293:620; Mantei, et al., 1979, *Nature* 281:40; and Levinson, et al., EP 117,060A and 117,058A. A particularly useful plasmid for mammalian cell culture expression of NT-4 is  
25 pRK5 (EP Pub. No. 307,247) or pSV16B (PCT Pub. No. WO90/08291, published 6/13/91).

Expression vectors, unlike cloning vectors, should contain a promoter which is recognized by the host organism and is operably linked to the NT-4 nucleic acid. Promoters are untranslated sequences located upstream from the start codon of a structural gene (generally within about 100 to 1000 bp) that control the transcription and translation of  
30 nucleic acid under their control. They typically fall into two classes, inducible and constitutive. Inducible promoters are promoters that initiate increased levels of transcription from DNA under their control in response to some change in culture conditions, e.g. the presence or absence of a nutrient or a change in temperature. At this time a large number of promoters recognized by a variety of potential host cells are well known. These promoters  
35 are operably linked to NT-4-encoding DNA by removing them from their gene of origin by restriction enzyme digestion, followed by insertion 5' to the start codon for NT-4. This is not to say that the genomic NT-4 promoter is not usable. However, heterologous promoters generally will result in greater transcription and higher yields of expressed NT-4.

Nucleic acid is operably linked when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein which participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, operably linked means that the DNA sequences being linked are contiguous and, in the case of a secretory leader, contiguous and in reading phase. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist then synthetic oligonucleotide adaptors or linkers are used in accord with conventional practice.

Promoters suitable for use with prokaryotic hosts include the  $\beta$ -lactamase and lactose promoter systems (Chang, et al., 1978, Nature 275:615; Goeddel, et al., 1979, Nature 281:544), alkaline phosphatase, a tryptophan (trp) promoter system (Goeddel, 1980, Nucleic Acids Res. 8:4057 and EPO Appln. Publ. No. 36,776) and hybrid promoters such as the tac promoter (H. de Boer, et al., 1983, Proc. Nat'l. Acad. Sci. 80:21). However, other known bacterial promoters are suitable. Their nucleotide sequences have been published, thereby enabling a skilled worker operably to ligate them to DNA encoding NT-4 (Siebenlist, et al., 1980, Cell 20:269) using linkers or adaptors to supply any required restriction sites. Promoters for use in bacterial systems also will contain a Shine-Dalgarno (S.D.) sequence operably linked to the DNA encoding NT-4.

Suitable promoting sequences for use with yeast hosts include the promoters for 3-phosphoglycerate kinase (Hitzeman, et al., 1980, J. Biol. Chem. 255:2073) or other glycolytic enzymes (Hess, et al., 1968, J. Adv. Enzyme Reg. 7:149; Holland, 1978, Biochemistry 17:4900), such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase.

Other yeast promoters, which are inducible promoters having the additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters for use in yeast expression are further described in R. Hitzeman, et al., EP 73,657A. Yeast enhancers also are advantageously used with yeast promoters.

Transcription of NT-4-encoding DNA in mammalian host cells is controlled by promoters obtained from the genomes of viruses such as polyoma, cytomegalovirus, adenovirus, retroviruses, hepatitis-B virus and most preferably Simian Virus 40 (SV40), or from heterologous mammalian promoters, e.g. the actin promoter. The early and late promoters of the SV40 virus are conveniently obtained as an SV40 restriction fragment which also

contains the SV40 viral origin of replication (Fiers, et al., 1978, Nature 273:113). Of course, promoters from the host cell or related species also are useful herein.

Transcription of NT-4-encoding DNA in mammalian host cells may be increased by inserting an enhancer sequence into the vector. An enhancer is a nucleotide sequence, usually about from 10-300 bp, that acts on a promoter to increase its transcription and does so in a manner that is relatively orientation and position independent. Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin,  $\alpha$ -fetoprotein and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenoviral enhancers. The enhancer may be spliced into the vector at a position 5' or 3' to the NT-4-encoding sequence, but is preferably located at a site 5' from the promoter.

Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, human or nucleated cells from other multicellular organisms) will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5' and, occasionally 3' untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain regions that are transcribed as polyadenylated segments in the untranslated portion of the mRNA encoding NT-4. The 3' untranslated regions also include transcription termination sites.

Suitable host cells for cloning or expressing the vectors herein are the prokaryote, yeast or higher eukaryote cells described above. Suitable prokaryotes include gram negative or gram positive organisms, for example *E. coli* or bacilli. A preferred cloning host is *E. coli* 294 (ATCC 31,446) although other gram negative or gram positive prokaryotes such as *E. coli* B, *E. coli* X1776 (ATCC 31,537), *E. coli* W3110 (ATCC 27,325), pseudomonas species, or *Serratia marcesans* are suitable.

In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable hosts for NT-4-encoding vectors. *Saccharomyces cerevisiae*, or common baker's yeast, is the most commonly used among lower eukaryotic host microorganisms. However, a number of other genera, species and strains are commonly available and useful herein.

Suitable host cells for the expression of NT-4 are derived from multicellular organisms. Such host cells are capable of complex processing and glycosylation activities. In principle, any higher eukaryotic cell culture is workable, whether from vertebrate or invertebrate culture, although cells from mammals such as humans are preferred. Propagation of such cells in culture is per se well known. (*Tissue Culture*, 1973, Kruse and Patterson, Eds., Academic Press, New York). Examples of useful mammalian host cell lines are VERO and HeLa cells, Chinese hamster ovary cell lines, the WI38, BHK, COS-7, MDCK cell lines and human embryonic kidney cell line 293.

Host cells are transformed with the above-described expression or cloning vectors and cultured in conventional nutrient media modified as is appropriate for inducing promoters or selecting transformants containing amplified genes. The culture conditions, such as temperature, pH and the like, suitably are those previously used with the host cell selected for cloning or expression, as the case may be, and will be apparent to the ordinary artisan.

NT-4 preferably is recovered from the culture medium as a secreted protein, although it also may be recovered from host cell lysates when directly expressed without a secretory signal. When NT-4 is expressed in a recombinant cell other than one of human origin, the NT-4 is thus completely free of proteins of human origin. However, it is necessary to purify NT-4 from recombinant cell proteins in order to obtain preparations that are substantially homogeneous as to protein. As a first step, the culture medium or lysate is centrifuged to remove particulate cell debris. NT-4 thereafter is purified from contaminant soluble proteins, for example, by fractionation on immunoaffinity or ion exchange columns; ethanol precipitation; reverse phase HPLC; chromatography on silica or on a cation exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; or gel electrophoresis using, for example, Sephadex G-75. NT-4 variants in which residues have been deleted, inserted or substituted relative to native NT-4 are recovered in the same fashion as native NT-4, taking account of any substantial changes in properties occasioned by the variation. For example, preparation of an NT-4 fusion with another protein, e.g. a bacterial or viral antigen, facilitates purification because an immunoaffinity column containing antibody to the antigen can be used to adsorb the fusion protein. A protease inhibitor such as phenyl methyl sulfonyl fluoride (PMSF) may be useful to inhibit proteolytic degradation during purification, and antibiotics may be included to prevent the growth of adventitious contaminants. One skilled in the art will appreciate that purification methods suitable for native NT-4 may require modification to account for changes in the character of NT-4 or its variants upon expression in recombinant cell culture.

Peptide fragments of NT-4 and modified forms of NT-4 also are included within the scope of this invention. Peptide fragments having up to about 40 amino residues may be conveniently prepared by in vitro synthesis.

Covalent modifications are made by reacting targeted amino acid residues of an NT-4 polypeptide or peptide fragment with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C-terminal residues.

Cysteinyl residues most commonly are reacted with  $\alpha$ -haloacetates (and corresponding amines), such as chloroacetic acid or chloroacetamide, to give carboxymethyl or carboxyamidomethyl derivatives. Cysteinyl residues also are derivatized by reaction with bromotrifluoroacetone,  $\alpha$ -bromo- $\beta$ -(5-imidazolyl)propionic acid, chloroacetyl phosphate, N-alkylmaleimides, 3-nitro-2-pyridyl disulfide, methyl 2-pyridyl disulfide, p-chloromercuribenzoate, 2-chloromercuri-4-nitrophenol, or chloro-7-nitrobenzo-2-oxa-1,3-diazole.

Histidyl residues are derivatized by reaction with diethylpyrocarbonate at pH 5.5-7.0 because this agent is relatively specific for the histidyl side chain. Para-bromophenacyl bromide also is useful; the reaction is preferably performed in 0.1M sodium cacodylate at pH 6.0.

5 Lysinyl and amino terminal residues are reacted with succinic or other carboxylic acid anhydrides. Derivatization with these agents has the effect of reversing the charge of the lysinyl residues. Other suitable reagents for derivatizing  $\alpha$ -amino-containing residues include imidoesters such as methyl picolinimide; pyridoxal phosphate; pyridoxal; chloroborohydride; trinitrobenzenesulfonic acid; O-methylisourea; 2,4-pentanedione; and transaminase-catalyzed  
10 reaction with glyoxylate.

Arginyl residues are modified by reaction with one or several conventional reagents, among them phenylglyoxal, 2,3-butanedione, 1,2-cyclohexanedione, and ninhydrin. Derivatization of arginine residues requires that the reaction be performed in alkaline conditions because of the high  $pK_a$  of the guanidine functional group. Furthermore, these  
15 reagents may react with the groups of lysine as well as the arginine epsilon-amino group.

The specific modification of tyrosyl residues may be made, with particular interest in introducing spectral labels into tyrosyl residues by reaction with aromatic diazonium compounds or tetranitromethane. Most commonly, N-acetylimidazole and tetranitromethane are used to form O-acetyl tyrosyl species and 3-nitro derivatives, respectively. Tyrosyl  
20 residues are iodinated using  $^{125}I$  or  $^{131}I$  to prepare labeled proteins for use in radioimmunoassay, the chloramine T method described above being suitable.

Carboxyl side groups (aspartyl or glutamyl) are selectively modified by reaction with carbodiimides ( $R'-N=C=N-R'$ ) such as 1-cyclohexyl-3-(2-morpholinyl-4-ethyl) carbodiimide or 1-ethyl-3-(4-azonia-4,4-dimethylpentyl) carbodiimide. Furthermore, aspartyl and glutamyl  
25 residues are converted to asparaginyl and glutaminyl residues by reaction with ammonium ions.

Derivatization with bifunctional agents is useful for crosslinking NT-4 to a water-insoluble support matrix or surface for use in the method for purifying anti-NT-4 antibodies, and vice versa. Commonly used crosslinking agents include, e.g., 1,1-bis(diazoacetyl)-2-  
30 phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azido-salicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-dithiobis(succinimidylpropionate), and bifunctional maleimides such as bis-N-maleimido-1,8-octane. Derivatizing agents such as methyl-3-[(p-azidophenyl)dithio]propioimide yield photoactivatable intermediates that are capable of forming crosslinks in the presence of light.  
35 Alternatively, reactive water-insoluble matrices such as cyanogen bromide-activated carbohydrates and the reactive substrates described in U.S. Pat. Nos. 3,969,287; 3,691,016; 4,195,128; 4,247,642; 4,229,537; and 4,330,440 are employed for protein immobilization.

Glutamyl and asparagyl residues are frequently deamidated to the corresponding glutamyl and aspartyl residues. Alternatively, these residues are deamidated under mildly acidic conditions. Either form of these residues falls within the scope of this invention.

5 Other modifications include hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the  $\alpha$ -amino groups of lysine, arginine, and histidine side chains (Creighton, Proteins: Structure and Molecular Properties, W.H. Freeman & Co., San Francisco, pp. 79-86), acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group. NT-4 also is covalently linked to  
10 nonproteinaceous polymers, e.g. polyethylene glycol, polypropylene glycol or polyoxyalkylenes, in the manner set forth in U.S. Pat. App. No. 07/275,296 or U.S. Pat. Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.

NT-4 in purified form, that is, in a form where the NT-4 is substantially free of other polypeptides or peptides, may be entrapped in microcapsules prepared, for example, by  
15 coacervation techniques or by interfacial polymerization (for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacrylate) microcapsules, respectively), in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences, 16th edition, 1980, (A. Osol, Ed).

20 NT-4 is believed to find use as an agent for enhancing the survival or inducing the outgrowth of nerve cells. It, therefore, is useful in the therapy of degenerative disorders of the nervous system ("neurodegenerative diseases"), including such diseases as Alzheimer's disease, Parkinson's disease, Huntington's chorea, ALS, peripheral neuropathies, and other conditions characterized by necrosis or loss of neurons, whether central, peripheral, or  
25 motoneurons. In addition, it may be useful for treating damaged nerve cells, e.g., nerves damaged by traumatic conditions such as burns and wounds, diabetes, kidney dysfunction, and the toxic effects of chemotherapeutics used to treat cancer and AIDS. It also is useful as a component of culture media for use in culturing nerve cells in vitro. Finally, NT-4 preparations are useful as standards in assays for NT-4 and in competitive-type receptor  
30 binding assays when labelled with radioiodine, enzymes, fluorophores, spin labels, and the like.

Therapeutic formulations of NT-4 are prepared for storage by mixing NT-4 having the desired degree of purity with optional physiologically acceptable carriers, excipients or  
35 stabilizers (Remington's Pharmaceutical Sciences, supra), in the form of lyophilized cake or aqueous solutions. Acceptable carriers, excipients or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone, amino acids such as



glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides and other carbohydrates including glucose, mannose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as Tween, Pluronics or PEG.

- 5 NT-4 to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes, prior to or following lyophilization and reconstitution. NT-4 ordinarily will be stored in lyophilized form.

- Therapeutic NT-4 compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by  
10 a hypodermic injection needle.

NT-4 optionally is combined with or administered in concert with other neurotrophic factors including NGF, NT-3, and/or BDNF and is used with other conventional therapies for degenerative nervous disorders.

- The route of NT-4 or NT-4 antibody administration is in accord with known methods,  
15 e.g. injection or infusion by intravenous, intraperitoneal, intracerebral, intramuscular, intraocular, intraarterial or intralesional routes, topical administration, or by sustained release systems as noted below. NT-4 is administered continuously by infusion into the fluid reservoirs of the CNS, although bolus injection is acceptable. NT-4 preferably is administered into the ventricles of the brain or otherwise introduced into the CNS or spinal fluid. It should  
20 be administered by an indwelling catheter using a continuous administration means such as a pump, or it can be administered by implantation, e.g., intracerebral implantation, of a sustained-release vehicle. More specifically, NT-4 can be injected through chronically implanted cannulas or chronically infused with the help of osmotic minipumps. Subcutaneous pumps are available that deliver proteins through a small tubing to the cerebral ventricles.  
25 Highly sophisticated pumps can be refilled through the skin and their delivery rate can be set without surgical intervention. Examples of suitable administration protocols and delivery systems involving a subcutaneous pump device or continuous intracerebroventricular infusion through a totally implanted drug delivery system are those used for the administration of dopamine, dopamine agonists, and cholinergic agonists to Alzheimer patients and animal  
30 models for Parkinson's disease described by Harbaugh, 1987, J. Neural Transm. Suppl., 24:271; and DeYebenes, et al., 1987, Mov. Disord. 2:143. NT-4 antibody is administered in the same fashion, or by administration into the blood stream or lymph.

- Suitable examples of sustained release preparations include semipermeable polymer matrices in the form of shaped articles, e.g. films, or microcapsules. Sustained release  
35 matrices include polyesters, hydrogels, polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma ethyl-L-glutamate (Sidman, et al., 1983, Biopolymers 22:547), poly (2-hydroxyethyl-methacrylate) (Langer, et al., 1981, J. Biomed. Mater. Res. 15:167; Langer, 1982, Chem. Tech. 12:98), ethylene vinyl acetate (Langer, et al., Id.) or poly-D-(-)-3-hydroxybutyric acid (EP 133,988A). Sustained release NT-4

compositions also include liposomally entrapped NT-4. Liposomes containing NT-4 are prepared by methods known per se. (Epstein, et al., 1985, Proc. Natl. Acad. Sci. 82:3688; Hwang, et al., 1980, Proc. Natl. Acad. Sci. USA 77:4030; DE 3,218,121A; EP 52322A; EP 36676A; EP 88046A; EP 143949A; EP 142641A; Japanese Pat. App. No. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324A). Ordinarily the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. % cholesterol, the selected proportion being adjusted for the optimal NT-4 therapy.

An effective amount of NT-4 to be employed therapeutically will depend, for example, upon the therapeutic objectives, the route of administration, and the condition of the patient. Accordingly, it will be necessary for the therapist to titer the dosage and modify the route of administration as required to obtain the optimal therapeutic effect. A typical daily dosage might range from about 1  $\mu$ g/kg to up to 100 mg/kg or more, depending on the factors mentioned above. Typically, the clinician will administer NT-4 until a dosage is reached that repairs, maintains, and, optimally, reestablishes neuron function. The progress of this therapy is easily monitored by conventional assays.

Polyclonal antibodies to NT-4 generally are raised in animals by multiple subcutaneous (sc) or intraperitoneal (ip) injections of NT-4 and an adjuvant. It may be useful to conjugate NT-4 or a fragment containing the target amino acid sequence to a protein which is immunogenic in the species to be immunized, e.g., keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor using a bifunctional or derivatizing agent, for example, maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine residues), N-hydroxysuccinimide (through lysine residues), glutaraldehyde, succinic anhydride,  $\text{SOCl}_2$ , or  $\text{R}^1\text{N} = \text{C} = \text{NR}$ .

Animals are immunized against the immunogenic conjugates or derivatives by combining 1 mg or 1  $\mu$ g of conjugate (for rabbits or mice, respectively) with 3 volumes of Freund's complete adjuvant and injecting the solution intradermally at multiple sites. One month later the animals are boosted with 1/5 to 1/10 the original amount of conjugate in Freund's complete adjuvant by subcutaneous injection at multiple sites. 7 to 14 days later animals are bled and the serum is assayed for anti-NT-4 titer. Animals are boosted until the titer plateaus. Preferably, the animal is boosted with the conjugate of the same NT-4 polypeptide, but conjugated to a different protein and/or through a different cross-linking agent. Conjugates also can be made in recombinant cell culture as protein fusions. Also, aggregating agents such as alum are used to enhance the immune response.

Monoclonal antibodies are prepared by recovering spleen cells from immunized animals and immortalizing the cells in conventional fashion, e.g. by fusion with myeloma cells or by EB virus transformation and screening for clones expressing the desired antibody.

NT-4 antibodies are useful in diagnostic assays for NT-4 or its antibodies. The antibodies are labelled in the same fashion as NT-4 described above and/or are immobilized

-21-

on an insoluble matrix. In one embodiment of a receptor binding assay, an antibody composition which binds to all or a selected plurality of members of the NT-4 family is immobilized on an insoluble matrix, the test sample is contacted with the immobilized antibody composition in order to adsorb all NT-4 family members, and then the immobilized family members are contacted with a plurality of antibodies specific for each member, each of the antibodies being individually identifiable as specific for a predetermined family member, as by unique labels such as discrete fluorophores or the like. By determining the presence and/or amount of each unique label, the relative proportion and amount of each family member can be determined.

NT-4 antibodies also are useful for the affinity purification of NT-4 from recombinant cell culture or natural sources. NT-4 antibodies that do not detectably cross-react with NGF, NT-3, or BDNF can be used to purify NT-4 free from these other family members.

Suitable diagnostic assays for NT-4 and its antibodies are well known per se. In addition to the bioassay described above, competitive, sandwich and steric inhibition immunoassay techniques are useful. The competitive and sandwich methods employ a phase separation step as an integral part of the method while steric inhibition assays are conducted in a single reaction mixture. Fundamentally, the same procedures are used for the assay of NT-4 and for substances that bind NT-4, although certain methods will be favored depending upon the molecular weight of the substance being assayed. Therefore, the substance to be tested is referred to herein as an analyte, irrespective of its status otherwise as an antigen or antibody, and proteins which bind to the analyte are denominated binding partners, whether they be antibodies, cell surface receptors or antigens.

Analytical methods for NT-4 or its antibodies all use one or more of the following reagents: labelled analyte analogue, immobilized analyte analogue, labelled binding partner, immobilized binding partner and steric conjugates. The labelled reagents also are known as "tracers".

The label used is any detectable functionality which does not interfere with the binding of analyte and its binding partner. Numerous labels are known for use in immunoassay, examples including enzymes such as horseradish peroxidase, radioisotopes such as  $^{14}\text{C}$  and  $^{131}\text{I}$ , fluorophores such as rare earth chelates or fluorescein, stable free radicals and the like. Conventional methods are available to covalently bind these labels to proteins or polypeptides. Such bonding methods are suitable for use with NT-4 or its antibodies, all of which are proteinaceous.

Immobilization of reagents is required for certain assay methods. Immobilization entails separating the binding partner from any analyte which remains free in solution. This conventionally is accomplished by either insolubilizing the binding partner or analyte analogue before the assay procedure, as by adsorption to a water insoluble matrix or surface (Bennich, et al., U.S. Pat. No. 3,720,760), by covalent coupling (for example using glutaraldehyde

cross-linking), or by insolubilizing the partner or analogue afterward, e.g., by immunoprecipitation.

Other assay methods, known as competitive or sandwich assays, are well established and widely used in the commercial diagnostics industry.

5 Competitive assays rely on the ability of a labelled analogue (the "tracer") to compete with the test sample analyte for a limited number of binding sites on a common binding partner. The binding partner generally is insolubilized before or after the competition and then the tracer and analyte bound to the binding partner are separated from the unbound tracer and analyte. This separation is accomplished by decanting (where the binding partner was  
10 preinsolubilized) or by centrifuging (where the binding partner was precipitated after the competitive reaction). The amount of test sample analyte is inversely proportional to the amount of bound tracer as measured by the amount of marker substance. Dose-response curves with known amounts of analyte are prepared and compared with the test results in order to quantitatively determine the amount of analyte present in the test sample. These  
15 assays are called ELISA systems when enzymes are used as the detectable markers.

Another species of competitive assay, called a "homogeneous" assay, does not require a phase separation. Here, a conjugate of an enzyme with the analyte is prepared and used such that when anti-analyte binds to the analyte the presence of the anti-analyte modifies the enzyme activity. In this case, NT-4 or its immunologically active fragments are conjugated  
20 with a bifunctional organic bridge to an enzyme such as peroxidase. Conjugates are selected for use with anti-NT-4 so that binding of the anti-NT-4 inhibits or potentiates the enzyme activity of the label. This method per se is widely practiced under the name of EMIT.

Steric conjugates are used in steric hindrance methods for homogeneous assay. These conjugates are synthesized by covalently linking a low molecular weight hapten to a small  
25 analyte so that antibody to hapten substantially is unable to bind the conjugate at the same time as anti-analyte. Under this assay procedure the analyte present in the test sample will bind anti-analyte, thereby allowing anti-hapten to bind the conjugate, resulting in a change in the character of the conjugate hapten, e.g., a change in fluorescence when the hapten is a fluorophore.

30 Sandwich assays particularly are useful for the determination of NT-4 or NT-4 antibodies. In sequential sandwich assays an immobilized binding partner is used to adsorb test sample analyte, the test sample is removed as by washing, the bound analyte is used to adsorb labelled binding partner and bound material then separated from residual tracer. The amount of bound tracer is directly proportional to test sample analyte. In "simultaneous"  
35 sandwich assays test sample is not separated before adding the labelled binding partner. A sequential sandwich assay using an anti-NT-4 monoclonal antibody as one antibody and a polyclonal anti-NT-4 antibody as the other is useful in testing samples for NT-4 activity.

The foregoing are merely exemplary diagnostic assays for NT-4 and antibodies. Other methods now or hereafter developed for the determination of these analytes are included within the scope hereof, including the bioassay described above.

The following examples are offered by way of illustration and not by way of limitation.

5

EXAMPLE I

Attempts to identify and isolate DNA encoding NT-4 from human genomic and cDNA libraries using NGF and BDNF probes were unsuccessful. Instead, to identify the NT-4 gene, it was necessary to amplify human genomic DNA using the polymerase chain reaction (PCR) (Mullis, et al., 1987, Cold Spring Harbor Symp. Quant. Biol. 51:263). Human genomic placental DNA (prepared as described in Maniatis, et al., 1982, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York, in the section on preparing a genomic DNA library) was employed as template for the above-identified primers, since the active forms of NGF, BDNF, and NT-3 are encoded by a single exon (Leibrock, et al., supra; Hohn, et al., supra; Maisonpierre, et al., supra; Rosenthal, et al., supra).

15 Amino acid sequences for NGF, BDNF, and NT-3 were scanned for regions of common homology. A number of these regions were identified and single stranded primer pools containing restriction sites for Sal, Xba, and EcoRI were prepared that were complementary to all possible sequences of DNA for the plus and minus strands of the selected NGF, BDNF, and NT-3 sequences. The primer pool for the sense strand corresponded to residues 50 - 58 of (mature human  $\beta$ NGF) NGF, designated NGX-54. The sense primer comprised the following sequence of alternatives (SEQ ID NOS. 93, 94, 95 and 96, respectively):

25 5'-CCGCGCGCTCTAGAGTCGACAAGCAGTACTTCTATGAGACGAAGTGT-3'  
   A  A  T  T  TC  A  CCGA  C  
   T  
   A

30 The primer pool for the antisense strand corresponded to residues 102 - 110 of NGF (designated AR1) and comprised the following sequence of alternatives (SEQ ID NOS. 97, 98, 99 and 100, respectively):

35 5'-CGGCTCAGGGCCGAATTCGCACACGCAGGAAGTATCTATCCTTAT-3'  
   A  T  A  A  CG  G  A  T  GG  
   G                  T      G  G  A  
   A

40 Note that each primer sequence has a restriction site at its 5' end in order to facilitate cloning the amplified sequences. Careful selection of amplification conditions allowed amplification of NT-4 sequence despite the fact that these pools were considerably larger than the conventional pools used heretofore for shorter amino acid sequences (ranging from 32 to 32,000 fold degeneracy. (Lee, et al., 1988, Science 239:1288; Strathmann, et al., 1989,

-24-

Proc. Nat. Acad. Sci. 86:7407; Leibrock, et al. supra). The primers were employed to prepare amplified DNA which was then sequenced. The conditions for amplification were as follows:

I. PCR with Human genomic placental DNA

- 5    denat. 95°C 5' once initially  
       denat. 95°C 1' }  
       anneal 55°C 1' } 45 cycles  
       extens. 72°C 1' }
- 10    extens. 72°C 15'
- 10  $\mu$ l 10x buffer (final = 50 mM KCl, 10 mM Tris pH 8.4, 3.0 mM MgCl<sub>2</sub>)  
       3  $\mu$ l human genomic DNA (3  $\mu$ g)  
       7.5 ng/ $\mu$ l primer (approx. 1  $\mu$ g = ~ 2.6  $\mu$ M of 33 mer,  
 15        therefore 10<sup>3</sup> degen = nM, 10<sup>6</sup> = pM)  
       7.5 ng/ $\mu$ l primer  
       10  $\mu$ l 10x dNTPs (final = 0.2 mM dNTPs)  
       1  $\mu$ l Taq polymerase  
       61  $\mu$ l dH<sub>2</sub>O
- 20    100  $\mu$ l V<sub>T</sub>

II. Cut with Sall and EcoRI, generate and gel purify fragments of the expected size, about 210 bp, and subclone into the M13-based vector, M13mp18 (Pharmacia).

- 25    NGF, BDNF, and NT-3 clones were identified by hybridization with oligonucleotides derived from unique regions of their respective cDNA sequences. Plasmids containing non-hybridizing inserts were sequenced (Smith, 1980, Meth. Enzymol. 65:560) and their potential translation products were analyzed for homology with NGF, BDNF, and NT-3.

- 30    This procedure revealed the presence of about 500 NGF, BDNF, and NT-3 clones, and 78 unrelated clones. In addition, three DNA fragments encoding part of a novel NGF-related factor were identified and collectively designated NT-4. The low abundance of NT-4 clones generated by PCR was caused by the poor homology between its DNA sequence and the PCR primers.

- 35    Screening of a human fetal brain cDNA library (Rosenthal, et al., 1987, EMBO J. 6:3641) using the genomic placental clone as a probe did not yield any positive clones. To obtain a complete human NT-4 homolog, a human genomic library was also screened (Maniatis, et al., 1978, Cell 15:687) and a 6-kb DNA fragment was isolated. This fragment was found to contain a single open reading frame encoding a polypeptide of 168 amino acids encompassing the NT-4 mature polypeptide.

- 40    The full nucleotide sequence and deduced amino acid sequence of human mature NT-4 and at least a portion of its precursor region is shown in Figure 1. The entire precursor region, including the signal sequence, may be as depicted between the initiating methionine

shown and the last Arg of the cleavage site before the mature sequence begins. If this is the case, the precursor region of NT-4 is much shorter than the precursor regions of NGF, BDNF, and NT-3, shown in Figure 2. Assignment of the initiation codon for NT-4 was made based on the location of the initiation codon in NGF, BDNF, and NT-3. The amino acid sequence of mature human NT-4 has approximately 46%, 55%, and 52% sequence homology (identity) to mature human NGF, BDNF, and NT-3, respectively, based on the alignment of the sequences as shown in Figure 2.

The active, mature forms of NGF, BDNF, and NT-3 are homodimers of 13-14 kD proteins that are generated from their ca. 30 kD precursors (Leibrock, et al., supra; Maisonpierre, et al., supra; Hohn, et al., supra; Greene and Shooter, 1980, Ann Rev. Neurosci. 3:353). The NT-4 precursor protein sequence also showed a potential tetrabasic cleavage site before the mature region begins, indicating that all four members of this protein family may be similarly processed. Processing at this site would result in a 13.14 kD (130 amino acid) polypeptide.

To assess the possible function of NT-4, its tissue distribution was determined by Northern blot analysis. In the rat, NT-4 mRNA was found in varying levels in every tissue examined, i.e., heart, muscle, kidney, liver, spleen, gut, lung, and spinal cord, and in several brain regions, including cerebellum and cortex. This broad organ localization of NT-4 mRNA suggested that in the peripheral nervous system, NT-4 could serve as a target-derived trophic factor for sympathetic, sensory, and/or motor neurons. This theory is tested by expressing DNA encoding recombinant human NT-4 and assaying its various activities.

#### EXAMPLE II

The following protocol for expressing NT-4 DNA and purifying the resultant NT-4 is expected to provide sufficient NT-4 for assay purposes. This example also provides expected assays to be employed to test the purified NT-4 and compare it to NGF.

A cytomegalovirus-based expression vector called pRK5, described in Gorman, et al., 1990, DNA and Protein Engineering Techniques 2:1 and in EP Pub. No. 307,247, published 15 March 1989, is employed as the expression vector. The NT-4 genomic DNA is cut from the phage in which it was cloned. This DNA fragment is then ligated into pRK5 previously cut with the appropriate restriction enzymes to accommodate the DNA fragment using standard ligation methodology (Maniatis et al., 1982, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York). The resulting vector is called pRK-5hNT-4.

A human embryonal kidney 293 cell line (Graham, et al., 1977, J. Gen. Virol. 36:59) is grown to confluence. Ten  $\mu$ g of the NT-4 plasmid DNA (pRK-5hNT-4) is mixed with 1  $\mu$ g of DNA encoding the VA RNA gene (Thimmappaya, et al., 1982, Cell 31:543) and dissolved in 500  $\mu$ l of 1 mM Tris-HCl, 0.1 mM EDTA, 0.227 M  $\text{CaCl}_2$ . Added to this (dropwise while vortexing) is 500  $\mu$ l of 50 mM HEPES (pH 7.35), 280 mM NaCl, 1.5 mM  $\text{NaPO}_4$ , and the precipitate is allowed to form for 10 min. at 25°C. The suspended precipitate is then added

to the cells (in 100 mM plate) and allowed to settle for four hours in the incubator. The medium is then aspirated off and 2 ml of 20% glycerol in phosphate-buffered saline is added for 30 sec. The cells are washed twice with 5 ml of serum-free medium, then fresh medium is added, and the cells are incubated for five days.

5        The 293 cells are also transfected in the same way with pRK5 alone.

Twenty-four hours after the transfections, the medium is replaced and cells are incubated for 12 hours in the presence of 200  $\mu\text{Ci/ml}$   $^{35}\text{S}$ -cysteine and 200  $\mu\text{Ci}$   $^{35}\text{S}$ -methionine. Conditioned medium is then collected, concentrated 5-fold by lyophilization, and loaded on a 15% SDS gel, which is subsequently enhanced, dried, and exposed to film for  
10       two hours. These data are expected to indicate the presence of a polypeptide of approximately the expected size (14-15 kD).

Large-scale expression of NT-4 is performed by transiently introducing by the dextran sulfate method (Sompayrac and Danna, 1981, Proc. Natl. Acad. Sci. 12:7575) 700  $\mu\text{g}$  of pRK-5hNT-4 into the human embryonal kidney 293 cell line grown to maximal density (1.5  
15       liters) in a 3-liter Belco microcarrier spinner flask. The cells are first concentrated from the spinner flask by centrifugation, and washed with phosphate-buffered saline (PBS), and the DNA-dextran precipitate is incubated on the cell pellet for four hours. The cells are treated with 20% glycerol for 90 seconds, washed with a medium such as 50:50 DMEM:F-12 medium, and re-introduced into a 3-liter spinner flask containing 1.5 liter of the above medium  
20       plus 5  $\mu\text{g/ml}$  bovine insulin and 0.1  $\mu\text{g/ml}$  bovine transferrin. The above protocol is performed for three separate 3-liter cultures.

After 4 days approximately 5 liters of conditioned media from the large-scale expression described above is centrifuged and filtered to remove cells and debris, and concentrated 100-fold. The buffer, salts, and other small molecules are exchanged by  
25       dialysis into 25 mM sodium borate, pH 9.0, and 4 M urea, and applied to a 5 cm. x 5 cm. DEAE Sepharose Fast-Flow ion-exchange chromatography column (Pharmacia, Inc.). The pH of column effluent (495 ml) is neutralized (pH 7.0) by the addition of 0.1 volume of 250 mM 3-(N-morpholino)propanesulfonic acid (MOPS) buffer to give a final composition of 25 mM MOPS, pH 7.0, and 4 M urea. This sample is applied to a 2.5 cm. x 2.5 cm. S-Sepharose  
30       ion-exchange chromatography column (Pharmacia), washed, and eluted with 25 mM MOPS, pH 7.0, 4 M urea, and 0.5 M NaCl (40 ml).

Two different assays indicate the presence of recombinant human NT-4 in the S-Sepharose salt eluant (130 ng/ml, 5  $\mu\text{g}$  total): 1) 48-hour neuronal survival and neurite outgrowth in three types of chick embryonal peripheral ganglionic neurons: paravertebral  
35       sympathetic chain ganglion neurons, spinal sensory neurons of dorsal root ganglia (lumbosacral region), and nodose ganglion neurons, and 2) immunocrossreactivity in an ELISA assay (Lucas, et al., 1989, J. Endocrinol. 120:449) utilizing polyclonal antibodies to human  $\beta$ -NGF, which can be generated as described above in the Description Section using  $\beta$ -NGF as immunogen rather than NT-4. The S-Sepharose eluant is dialyzed into 1 M acetic acid and



4 M urea, concentrated 10-fold, applied to a S-300 Sephacryl gel-filtration column (1.5 cm. x 44 cm.), and chromatographed in the same buffer.

5 Aliquots of 200  $\mu$ l are taken from each 1 ml fraction collected, dialyzed against 1 M acetic acid, lyophilized, and redissolved in 30  $\mu$ l Laemmli SDS-PAGE sample buffer (Laemmli, 1970, Nature 227:680). Human  $\beta$ -NGF is obtained in a similar manner. Following SDS-PAGE, the silver-stained gel indicates a single, prominently stained polypeptide of approximately 15 kD. A 3-ml pool of S-300 column eluted fractions corresponding to this SDS-PAGE analyzed region is made, and 1 ml (0.5 nmole) is submitted to N-terminal amino acid sequence analysis by Edman degradation performed on a prototype automated amino acid sequencer (Kohr, EP Pat. Pub. No. 257,735). N-terminal sequence analysis gives a single sequence starting with a glycine residue predicted by the tetrabasic cleavage sequence ending in an arginine, and predicted by the processing of preproNGF to mature  $\beta$ -NGF.

10 The initial sequencing cycles may be quantitated to indicate the amount of recovery of the purified human NT-4 from the three-column process. The purified recombinant human NT-4 is dialyzed into 0.1% acetic acid to give a final concentration of 3.25  $\mu$ g/ml. This stock material may be diluted into neuronal cell media (DMEM high glucose with 10% fetal bovine serum) at various concentrations from 4 to 60 ng/ml for carrying out various bioassays.

15 For larger-scale production of NT-4, the preferred vector is a SV40-driven vector such as pSV16B described above, the preferred host cells are Chinese hamster ovary cells, and the preferred culture medium is a DMEM or 1:1 DMEM:F12 medium with levels of glucose elevated to optimize product yield or the serum-free medium described in U.S. Pat. No. 4,767,704.

20 Purified NT-4 is analyzed for neurotrophic activities on several types of primary embryonal day-10 chick neurons as described by Davies, in Nerve Growth Factors, 1989, (R.A. Rush, Ed., John Wiley & Sons, Boston), pp. 95-109. Thus, paravertebral sympathetic chain ganglia (SG), dorsal root (lumbosacral) ganglia (DRG), and nodose ganglia (NG) are dissected from day-10 chick embryos. The neuronal cells are dispersed from the ganglia with trypsin or pancreatin (GIBCO) and preplated twice to reduce the number of non-neuronal cells. Cells are counted and seeded in a 96-well tissue culture plate that had been pretreated with polyornithine (500  $\mu$ g/ml) and laminin (10  $\mu$ g/ml). (Lindsay, et al., 1985, Dev. Biol. 112:319). The cell seeding numbers are SG and DRG, 4000 cells per well; NG, 2000 cells per well.

30 Purified mouse submaxillary gland  $\beta$ -NGF used in the assays is obtained from Biomedical Technologies, Inc. and dissolved in 0.1% acetic acid to a concentration of 10  $\mu$ g/ml. Purified recombinant human NT-4 dialyzed into 0.1% acetic acid at a final concentration of 3.25  $\mu$ g/ml is used. Cells are incubated with or without the factors for 48 hours and phase-bright cell bodies which had elaborated neurites 5x the length of the cell body are counted. Individual perikaryons can be counted in the cultures of DRG and NG neurons. However, the perikaryons of SG neurons aggregate and cell aggregates are scored. The cell survival at maximal response is approximately 20-40% for DRG and NG neurons,

whereas SG neurons are likely higher since aggregates are scored. Four experiments are carried out utilizing each of NGF and NT-4.

NT-4 is expected to be most active on peripheral neurons. In vertebrates, peripheral neurons are derived from two distinct embryonic sources: the neural crest and the neural placodes (LeDouarin and Smith, 1988, *Ann. Rev. Cell Biol.* **4**:375). Neural crest-derived cells give rise to neurons and to the supporting cells of the peripheral nervous system and the placode-derived cells give rise to some sensory cells and cranial neurons.

The neural crest-derived dorsal root sensory ganglia (DRG) cells project to the CNS and to peripheral tissues, and are dependent on neurotrophic factors derived from both targets. (Lindsay, et al., 1985, *Dev. Biol.* **112**:319). This dual dependency is a possible mechanism to ensure the survival only of neurons that form all the appropriate connections. Placode-derived nodose sensory ganglia (NG), which are also dually connected and respond to the CNS factor BDNF, do not respond to the peripherally derived trophic factor (NGF). Thus, peripheral target innervation by NG neurons is likely to be ensured by an alternative mechanism or via other factors.

The presence of NT-4 in the brain and the periphery suggests additional functions and raises the possibility that it could be valuable for treating diseases such as Alzheimer's, Parkinson's, or Huntington's chorea that are caused by brain neuron degeneration and/or treating damaged nerves due to trauma or preventing damage to peripheral nerve cells. NT-4 could be tested for central neurological functions in an established animal lesion model such as that of Hefti, *supra*, or in aged rats or monkeys.

### EXAMPLE III

To identify naturally occurring amino acid sequence variants of NT-4, the genomic DNA fragment described above, comprising the coding sequence for mature human NT-4, was used as a hybridization probe to screen for homologous DNAs in the human fetal brain cDNA library (Rosenthal, et al., 1987, *EMBO J.*, **6**:3641) and in a human lymphocyte genomic DNA library (Stratagene, La Jolla, CA).

Hybridization and washing of filters containing the library DNAs were performed under high stringency conditions: Hybridization of radiolabelled NT-4 probe to the filters was performed in a solution of 50% formamide, 5x SSC (1x = 0.15 M NaCl, 0.015 M sodium citrate), 0.1% sodium dodecyl sulfate (SDS), 0.1% sodium pyrophosphate, 50mM sodium phosphate pH 6.8, 2x Denhardt's solution (1x = 0.02% Ficoll, 0.02% polyvinylpyrrolidone, 0.02% bovine serum albumin), 10% dextran sulfate, at 42°C. for 20 hrs. Washing of the filters was performed in an aqueous solution of 0.1x SSC, 0.1% SDS at 42°C.

Three DNAs were identified that had significant sequence homology with the DNA encoding mature human NT-4. The complete nucleotide sequences of those homologous DNAs is shown in Figures 3, 4, and 5, along with the deduced amino acid sequence of the polypeptides they encode, which polypeptides are referred to as NT-4 $\beta$ , NT-4 $\gamma$ , and NT-4 $\Delta$ , respectively. The DNA encoding human NT-4 $\beta$ , having the sequence shown in Figure 3, was

isolated from the human fetal brain cDNA library. The nucleotide sequence shown in Figure 3 appears to encode a portion of human NT-4 $\beta$ . A full length cDNA, encoding the entirety of human NT-4 $\beta$ , is readily obtained by probing the human fetal brain cDNA library with the cDNA disclosed in Figure 3. The DNA encoding human NT-4 $\gamma$ , having the sequence shown in Figure 4, was isolated from the human lymphocyte genomic DNA library. The DNA encoding human NT-4 $\Delta$ , having the sequence shown in Figure 5, also was isolated from the human lymphocyte genomic DNA library.

Figure 6 shows the homologies among the amino acid sequences of human NT-4, NT-4 $\beta$ , NT-4 $\gamma$ , and NT-4 $\Delta$ . The amino acid sequence of human NT-4 has at least about 75% sequence homology (identity) to each of NT-4 $\beta$ , NT-4 $\gamma$ , and NT-4 $\Delta$ , based on the alignment of the amino acid sequences as shown in Figure 6. As is apparent, NT-4 $\beta$ , NT-4 $\gamma$ , and NT-4 $\Delta$  are amino acid sequence variants of human NT-4, as defined herein, differing from human NT-4 by virtue of various amino acid insertions, and substitution.

Because NT-4 $\beta$ , NT-4 $\gamma$ , and NT-4 $\Delta$  are naturally occurring amino acid sequence variants of human NT-4, it is expected that NT-4 $\beta$ , NT-4 $\gamma$ , and NT-4 $\Delta$ , like NT-4, have a role in regulating the normal growth and/or development of vertebrate neural tissue. NT-4 $\beta$ , NT-4 $\gamma$ , and NT-4 $\Delta$  are readily produced by recombinant means by expression in a suitable host cell transformed with an expression vector comprising DNA encoding those polypeptides, as described above. NT-4 $\beta$ , NT-4 $\gamma$ , and NT-4 $\Delta$  are analyzed for neurotrophic activities as described above for NT-4.

In summary, NT-4 is a novel trophic factor with a broad tissue distribution. It complements NGF, BDNF, and NT-3, which are trophic factors for some peripheral neurons. NT-4 $\beta$ , NT-4 $\gamma$ , and NT-4 $\Delta$  are novel amino acid sequence variants of NT-4. Each of these factors can likely act alone or in concert on defined subsets of neurons to achieve the correct neuronal connections both in the peripheral and central nervous system.

-30-

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- 5 (i) APPLICANT: GENENTECH, INC.  
ROSENTHAL, ARNON
- (ii) TITLE OF INVENTION: NOVEL NEUROTROPHIC FACTOR
- 10 (iii) NUMBER OF SEQUENCES: 100
- (iv) CORRESPONDENCE ADDRESS:  
5 (A) ADDRESSEE: Genentech, Inc.  
6 (B) STREET: 460 Point San Bruno Blvd  
7 (C) CITY: South San Francisco  
8 (D) STATE: California  
9 (E) COUNTRY: USA  
10 (F) ZIP: 94080
- 20 (v) COMPUTER READABLE FORM:  
21 (A) MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk  
22 (B) COMPUTER: IBM PC compatible  
23 (C) OPERATING SYSTEM: PC-DOS/MS-DOS  
24 (D) SOFTWARE: patin (Genentech)
- 25 (vi) CURRENT APPLICATION DATA:  
26 (A) APPLICATION NUMBER:  
27 (B) FILING DATE: 24-SEP-1991  
28 (C) CLASSIFICATION:
- 30 (vii) PRIOR APPLICATION DATA:  
31 (A) APPLICATION NUMBER: 07/648482  
32 (B) APPLICATION DATE: 31-JAN-1991
- 35 (vii) PRIOR APPLICATION DATA:  
36 (A) APPLICATION NUMBER: 07/587707  
37 (B) APPLICATION DATE: 25-SEP-1990
- 40 (viii) ATTORNEY/AGENT INFORMATION:  
41 (A) NAME: Hensley, Max D.  
42 (B) REGISTRATION NUMBER: 27,043  
43 (C) REFERENCE/DOCKET NUMBER: 666P2
- 45 (ix) TELECOMMUNICATION INFORMATION:  
46 (A) TELEPHONE: 415/266-1994  
47 (B) TELEFAX: 415/952-9881  
48 (C) TELEX: 910/371-7168
- (2) INFORMATION FOR SEQ ID NO:1:
- 50 (i) SEQUENCE CHARACTERISTICS:  
51 (A) LENGTH: 634 bases  
52 (B) TYPE: nucleic acid  
53 (C) STRANDEDNESS: single  
54 (D) TOPOLOGY: linear
- 55 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
- 60 ATGCTCCCTC TCCCCTCATG CTCCCTCCCC ATCCTCCTCC TTTTCCTCCT 50
- CCCCAGTGTG CCAATTGAGT CCAAACCCCC ACCCTCAACA TTGCCCCCTT 100
- 65 TTCTGGCCCC TGAGTGGGAC CTTCTCTCCC CCGAGTAGT CCTGTCTAGG 150
- GGTGCCCCCTG CTGGGCCCCC TCTGCTCTTC CTGCTGGAGG CTGGGGCCTT 200

-31-

TCGGGAGTCA GCAGGTGCCC CGGCCAACCG CAGCCGGCGT GGGGTGAGCG 250  
 5 AAACTGCACC AGCGAGTCGT CGGGGTGAGC TGGCTGTGTG CGATGCAGTC 300  
 AGTGGCTGGG TGACAGACCG CCGGACCGCT GTGGACTTGC GTGGGCGCGA 350  
 10 GGTGGAGGTG TTGGGCGAGG TGCCTGCAGC TGGCGGCAGT CCCCTCCGCC 400  
 AGTACTTCTT TGAACCCGC TGCAAGGCTG ATAACGCTGA GGAAGGTGGC 450  
 15 CCGGGGGCAG GTGGAGGGGG CTGCCGGGGA GTGGACAGGA GGCAGTGGGT 500  
 ATCTGAGTGC AAGGCCAAGC AGTCCTATGT GCGGGCATTG ACCGCTGATG 550  
 20 CCCAGGGCCG TGTGGGCTGG CGATGGATTC GAATTGACAC TGCCTGCGTC 600  
 25 TGCACACTCC TCAGCCGGAC TGGCCGGGCC TGAG 634

## (2) INFORMATION FOR SEQ ID NO:2:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 210 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Leu Pro Leu Pro Ser Cys Ser Leu Pro Ile Leu Leu Leu Phe  
 1 5 10 15  
 Leu Leu Pro Ser Val Pro Ile Glu Ser Gln Pro Pro Pro Ser Thr  
 20 25 30  
 45 Leu Pro Pro Phe Leu Ala Pro Glu Trp Asp Leu Leu Ser Pro Arg  
 35 40 45  
 Val Val Leu Ser Arg Gly Ala Pro Ala Gly Pro Pro Leu Leu Phe  
 50 55 60  
 Leu Leu Glu Ala Gly Ala Phe Arg Glu Ser Ala Gly Ala Pro Ala  
 65 70 75  
 55 Asn Arg Ser Arg Arg Gly Val Ser Glu Thr Ala Pro Ala Ser Arg  
 80 85 90  
 Arg Gly Glu Leu Ala Val Cys Asp Ala Val Ser Gly Trp Val Thr  
 95 100 105  
 60 Asp Arg Arg Thr Ala Val Asp Leu Arg Gly Arg Glu Val Glu Val  
 110 115 120  
 Leu Gly Glu Val Pro Ala Ala Gly Gly Ser Pro Leu Arg Gln Tyr  
 125 130 135  
 65 Phe Phe Glu Thr Arg Cys Lys Ala Asp Asn Ala Glu Glu Gly Gly  
 140 145 150  
 Pro Gly Ala Gly Gly Gly Gly Cys Arg Gly Val Asp Arg Arg His

-32-

	155		160		165
	Trp Val Ser Glu Cys Lys Ala Lys Gln Ser Tyr Val Arg Ala Leu				
	170		175		180
5	Thr Ala Asp Ala Gln Gly Arg Val Gly Trp Arg Trp Ile Arg Ile				
	185		190		195
10	Asp Thr Ala Cys Val Cys Thr Leu Leu Ser Arg Thr Gly Arg Ala				
	200		205		210

## (2) INFORMATION FOR SEQ ID NO:3:

15 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 247 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

	Met Thr Ile Leu Phe Leu Thr Met Val Ile Ser Tyr Phe Gly Cys		
	1	5	10
25	Met Lys Ala Ala Pro Met Lys Glu Ala Asn Ile Arg Gly Gln Gly		
	20	25	30
	Gly Leu Ala Tyr Pro Gly Val Arg Thr His Gly Thr Leu Glu Ser		
	35	40	45
30	Val Asn Gly Pro Lys Ala Gly Ser Arg Gly Leu Thr Ser Leu Ala		
	50	55	60
35	Asp Thr Phe Glu His Met Ile Glu Glu Leu Leu Asp Glu Asp Gln		
	65	70	75
	Lys Val Arg Pro Asn Glu Glu Asn Asn Lys Asp Ala Asp Leu Tyr		
	80	85	90
40	Thr Ser Arg Val Met Leu Ser Ser Gln Val Pro Leu Glu Pro Pro		
	95	100	105
	Leu Leu Phe Leu Leu Glu Glu Tyr Lys Asn Tyr Leu Asp Ala Ala		
	110	115	120
45	Asn Met Ser Met Arg Val Arg Arg His Ser Asp Pro Ala Arg Arg		
	125	130	135
	Gly Glu Leu Ser Val Cys Asp Ser Ile Ser Glu Trp Val Thr Ala		
	140	145	150
50	Ala Asp Lys Lys Thr Ala Val Asp Met Ser Gly Gly Thr Val Thr		
	155	160	165
55	Val Leu Glu Lys Val Pro Val Ser Lys Gly Gln Leu Lys Gln Tyr		
	170	175	180
	Phe Tyr Glu Thr Lys Cys Asn Pro Met Gly Tyr Thr Lys Glu Gly		
	185	190	195
60	Cys Arg Gly Ile Asp Lys Arg His Trp Asn Ser Gln Cys Arg Thr		
	200	205	210
65	Thr Gln Ser Tyr Val Arg Ala Leu Thr Met Asp Ser Lys Lys Arg		
	215	220	225
	Ile Gly Trp Arg Phe Ile Arg Ile Asp Thr Ser Cys Val Cys Thr		
	230	235	240

-33-

Leu Thr Ile Lys Arg Gly Arg  
245 247

## (2) INFORMATION FOR SEQ ID NO:4:

5

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 257 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

10

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met Ser Ile Leu Phe Tyr Val Ile Phe Leu Ala Tyr Leu Arg Gly  
1 5 10 15  
Ile Gln Gly Asn Asn Met Asp Gln Arg Ser Leu Pro Glu Asp Ser  
20 25 30  
Leu Asn Ser Leu Ile Ile Lys Leu Ile Gln Ala Asp Ile Leu Lys  
35 40 45  
Asn Lys Leu Ser Lys Gln Met Val Asp Val Lys Glu Asn Tyr Gln  
50 55 60  
Ser Thr Leu Pro Lys Ala Glu Ala Pro Arg Glu Pro Glu Arg Gly  
65 70 75  
Gly Pro Ala Lys Ser Ala Phe Gln Pro Val Ile Ala Met Asp Thr  
80 85 90  
Glu Leu Leu Arg Gln Gln Arg Arg Tyr Asn Ser Pro Arg Val Leu  
95 100 105  
Leu Ser Asp Ser Thr Pro Leu Glu Pro Pro Pro Leu Tyr Leu Met  
110 115 120  
Glu Asp Tyr Val Gly Ser Pro Val Val Ala Asn Arg Thr Ser Arg  
125 130 135  
Arg Lys Arg Tyr Ala Glu His Lys Ser His Arg Gly Glu Tyr Ser  
140 145 150  
Val Cys Asp Ser Glu Ser Leu Trp Val Thr Asp Lys Ser Ser Ala  
155 160 165  
Ile Asp Ile Arg Gly His Gln Val Thr Val Leu Gly Glu Ile Lys  
170 175 180  
Thr Gly Asn Ser Pro Val Lys Gln Tyr Phe Tyr Glu Thr Arg Cys  
185 190 195  
Lys Glu Ala Arg Pro Val Lys Asn Gly Cys Arg Gly Ile Asp Asp  
200 205 210  
Lys His Trp Asn Ser Gln Cys Lys Thr Ser Gln Thr Tyr Val Arg  
215 220 225  
Ala Leu Thr Ser Glu Asn Asn Lys Leu Val Gly Trp Arg Trp Ile  
230 235 240  
Arg Ile Asp Thr Ser Cys Val Cys Ala Leu Ser Arg Lys Ile Gly  
245 250 255  
Arg Thr  
257

## (2) INFORMATION FOR SEQ ID NO:5:

## (i) SEQUENCE CHARACTERISTICS:

-34-

(A) LENGTH: 241 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

## 5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

```

Met Ser Met Leu Phe Tyr Thr Leu Ile Thr Ala Phe Leu Ile Gly
 1          5          10          15
10 Ile Gln Ala Glu Pro His Ser Glu Ser Asn Val Pro Ala Gly His
    20          25          30
    Thr Ile Pro Gln Val His Trp Thr Lys Leu Gln His Ser Leu Asp
    35          40          45
15 Thr Ala Leu Arg Arg Ala Arg Ser Ala Pro Ala Ala Ala Ile Ala
    50          55          60
20 Ala Arg Val Ala Gly Gln Thr Arg Asn Ile Thr Val Asp Pro Arg
    65          70          75
    Leu Phe Lys Lys Arg Arg Leu Arg Ser Pro Arg Val Leu Phe Ser
    80          85          90
25 Thr Gln Pro Pro Arg Glu Ala Ala Asp Thr Gln Asp Leu Asp Phe
    95          100          105
    Glu Val Gly Gly Ala Ala Pro Phe Asn Arg Thr His Arg Ser Lys
    110          115          120
30 Arg Ser Ser Ser His Pro Ile Phe His Arg Gly Glu Phe Ser Val
    125          130          135
35 Cys Asp Ser Val Ser Val Trp Val Gly Asp Lys Thr Thr Ala Thr
    140          145          150
    Asp Ile Lys Gly Lys Glu Val Met Val Leu Gly Glu Val Asn Ile
    155          160          165
40 Asn Asn Ser Val Phe Lys Gln Tyr Phe Phe Glu Thr Lys Cys Arg
    170          175          180
    Asp Pro Asn Pro Val Asp Ser Gly Cys Arg Gly Ile Asp Ser Lys
    185          190          195
45 His Trp Asn Ser Tyr Cys Thr Thr Thr His Thr Phe Val Lys Ala
    200          205          210
    Leu Thr Met Asp Gly Lys Gln Ala Ala Trp Arg Phe Ile Arg Ile
    215          220          225
50 Asp Thr Ala Cys Val Cys Val Leu Ser Arg Lys Ala Val Arg Arg
    230          235          240
55 Ala
    241

```

## (2) INFORMATION FOR SEQ ID NO:6:

60 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 168 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

## 65 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

```

Ser Pro Arg Val Val Leu Ser Arg Gly Ala Pro Ala Gly Pro Pro
 1          5          10          15

```



-35-

Leu Leu Phe Leu Leu Glu Ala Gly Ala Phe Arg Glu Ser Ala Gly  
                             20                            25                            30  
 5 Ala Pro Ala Asn Arg Ser Arg Arg Gly Val Ser Glu Thr Ala Pro  
                             35                            40                            45  
 Ala Ser Arg Arg Gly Glu Leu Ala Val Cys Asp Ala Val Ser Gly  
                             50                            55                            60  
 10 Trp Val Thr Asp Arg Arg Thr Ala Val Asp Leu Arg Gly Arg Glu  
                             65                            70                            75  
 Val Glu Val Leu Gly Glu Val Pro Ala Ala Gly Gly Ser Pro Leu  
                             80                            85                            90  
 15 Arg Gln Tyr Phe Phe Glu Thr Arg Cys Lys Ala Asp Asn Ala Glu  
                             95                            100                            105  
 Glu Gly Gly Pro Gly Ala Gly Gly Gly Gly Cys Arg Gly Val Asp  
                             110                            115                            120  
 20 Arg Arg His Trp Val Ser Glu Cys Lys Ala Lys Gln Ser Tyr Val  
                             125                            130                            135  
 25 Arg Ala Leu Thr Ala Asp Ala Gln Gly Arg Val Gly Trp Arg Trp  
                             140                            145                            150  
 Ile Arg Ile Asp Thr Ala Cys Val Cys Thr Leu Leu Ser Arg Thr  
                             155                            160                            165  
 30 Gly Arg Ala  
                             168

## (2) INFORMATION FOR SEQ ID NO:7:

35

## (i) SEQUENCE CHARACTERISTICS:

40

- (A) LENGTH: 685 bases
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

45

CGAGAGATGC TCTGAGAGAT GCTCCCACTC CCCCAGGCTC CCTCCGCATC 50

CCCCTCATTT TCCTCCTCCC CAGTGTGTCA ATGGAGTCCT AACCCCATCC 100

50

TCGACATTGT CGCCTTTTCC TCCTCCAGAG TGGGACCTTC TTTTCCCCCG 150

55

AGTGGTCCTG TCTAGGGGTG CCGCTGCCGG GCCCCCTCTG GTCTTCCTGC 200

TGGAGACTGG AGCCTTTTCGG GAGTCAGCAG GCGCCCGGGC CAACCGCAGC 250

60

CAGCCAGGGG TGAGCGATAC TTCACCGGCG AGTCATCAGG GTGAGCTGGC 300

CGTGTGCGAT GCAGTCAGTG TCTGGGTGAC AGACCCCTGG ACTGCTGTGG 350

65

ACTTGGGTGT GCTCGAGGTG GAGGTGTTGG GCGAGGTGCC TGCAGCTGTC 400

GGCAGTTCCC TCCGCCAGCA CTTCTTTGTT GCCCGCTTCG AGGCCGATAA 450

-36-

ATCTGAGGAA GGTGGCCCGG GGGTAGGTGG AGGGGCTGCC GCCGGGGTGT 500  
 5 GGACCGGGGG GCACTGGGTG TCTGAGTGCA AGGCCAAGCA GTCCTATGTG 550  
 CGGGCATTGA CCGCTGATGC CCAGGGCCGT GTGGACTGGC GATGGATTCA 600  
 10 AATTGGCACA GCCTGTGTCT GCACACTCCT CAGCCGGACT GGCCGGGCCT 650  
 GAGACTTATA CCCAGGAAGT GGTCAGGCAG AAAAA 685  
 15

## (2) INFORMATION FOR SEQ ID NO:8:

20 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 216 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

## 25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

	Glu	Arg	Cys	Ser	Glu	Arg	Cys	Ser	His	Ser	Pro	Arg	Leu	Pro	Pro	
	1				5					10				15		
30	His	Pro	Pro	His	Phe	Pro	Pro	Pro	Gln	Cys	Val	Asn	Gly	Val	Leu	
					20					25				30		
	Thr	Pro	Ser	Ser	Thr	Leu	Ser	Pro	Phe	Pro	Pro	Pro	Glu	Trp	Asp	
35					35					40				45		
	Leu	Leu	Phe	Pro	Arg	Val	Val	Leu	Ser	Arg	Gly	Ala	Ala	Ala	Gly	
					50					55				60		
40	Pro	Pro	Leu	Val	Phe	Leu	Leu	Glu	Thr	Gly	Ala	Phe	Arg	Glu	Ser	
					65					70				75		
	Ala	Gly	Ala	Arg	Ala	Asn	Arg	Ser	Gln	Arg	Gly	Val	Ser	Asp	Thr	
					80					85				90		
45	Ser	Pro	Ala	Ser	His	Gln	Gly	Glu	Leu	Ala	Val	Cys	Asp	Ala	Val	
					95					100				105		
	Ser	Val	Trp	Val	Thr	Asp	Pro	Trp	Thr	Ala	Val	Asp	Leu	Gly	Val	
50					110					115				120		
	Leu	Glu	Val	Glu	Val	Leu	Gly	Glu	Val	Pro	Ala	Ala	Val	Gly	Ser	
					125					130				135		
55	Ser	Leu	Arg	Gln	His	Phe	Phe	Val	Ala	Arg	Phe	Glu	Ala	Asp	Lys	
					140					145				150		
	Ser	Glu	Glu	Gly	Gly	Pro	Gly	Val	Gly	Gly	Gly	Ala	Ala	Ala	Gly	
					155					160				165		
60	Val	Trp	Thr	Gly	Gly	His	Trp	Val	Ser	Glu	Cys	Lys	Ala	Lys	Gln	
					170					175				180		
	Ser	Tyr	Val	Arg	Ala	Leu	Thr	Ala	Asp	Ala	Gln	Gly	Arg	Val	Asp	
					185					190				195		
65	Trp	Arg	Trp	Ile	Gln	Ile	Gly	Thr	Ala	Cys	Val	Cys	Thr	Leu	Leu	
					200					205				210		
	Ser	Arg	Thr	Gly	Arg	Ala										

-37-

215 216

## (2) INFORMATION FOR SEQ ID NO:9:

- 5 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 1190 bases  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
10 (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

15 ACTGGAGCGC AGCACCACGC CCAGCTAATT TTGGTATTAT CAGTAGAGAT 50  
GTTGTTTCAC AGTGTGGGCC AGGCTGCTCT CAAACTCCTG ACCTCAAGTC 100  
20 AAACACCCGC CTCAGCCTCC CAAAGTGCTG GGACTACAGG TGTGAGCCAT 150  
AGTGCCTGAC CTGTAGTTGT TGAATATTTA TTATTAATCT ACAAGTTGGG 200  
25 TGTGATGCAA GTCCTTTATA TGGAGTCCCC CAAACTTCTA GAGCAAGGGC 250  
TTCCCCATAA TCCTGGCAGG CAGGCCTCCC CTGGGGTTCC CAACTTCTGA 300  
30 CCCCCTGAA GTGTTTATCT TCTTCCCTAA TCCCAGCCTC CTTTTCCCTG 350  
35 TCTCCATGTG CTCTGAGAGA TGCTCTGAGA GATGCTCCTG CTCCCCCAGG 400  
CTCCCTCCGC ATCCCCCTCA TTTTCTCCTC CCCCAGTGTG TCATTGGAGT 450  
40 CCTAACCCCA TCCTCGACAT TGTCGCGTTT TCCTCCTCCA GAGTGGGACC 500  
TTCTTTTCCC CCGAGTGGTC CTGTCTAGGG GTGCCGCTGC CGGGCCCCCT 550  
45 CTGGTCTTCC TGCTGGAGAC TGGAGCCTTT CGGGAGTCAG CAGGCGCCCG 600  
50 GGCCAACCGC AGCCAGCGTG GGGTGAGCGA TACTTCACCG GTGAGTCATC 650  
AGGGTGAGCT GGCCGTGTGC GATGCAGTCA CTGTCTGGGT GACAGACCCC 700  
55 TGGACTGCTG TGGACTTGGG TGTGCTCGAG GTGGAGGTGT TGGGTGAGGT 750  
GCCTGCAGCT GGCAGCAGTT CCCTCCGCCA GCACTTCTTT GTTACCCGCT 800  
60 TCGAGGCCGA TAAATCTAAG GAAGGTGGCC CGGGGGTAGG TGGAGGACCT 850  
65 GCCGCCGGGG TGTGGACCGG GGGGCACTGG GTGTCTGAGT GCAAGGCCAA 900  
GCAGTCCTAT GGGCGGGCAT TGACCACTGA TGCCAGGGC CGTGTGGACT 950

-38-

GGCGATGGAT TCAAATTGGC ACTGCCTGTG TCTGCACACT CCTCAGCCGG 1000  
 ACTGGCCGGG CCTGAGACTT ATACCCAGGA ACTGGTCAGG CAGAAAAAGA 1050  
 ACAGAGCTGG ATGCTGAGAG ACCTCAGGGT TGGCCCAGCT GCTCTACGGA 1100  
 CGGACCCAG TGGGGAACT CATCAAATCA TCGCAAATC TCAACTGTCT 1150  
 GAATTGAGC TCAATCTCTG TAGGATGGGT GCAACAATGT 1190

## (2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 257 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

25 Ser Lys Gly Phe Pro Ile Ile Leu Ala Gly Arg Pro Pro Leu Gly  
 1 5 10 15  
 30 Phe Pro Thr Ser Asp Pro Thr Glu Val Phe Ile Phe Phe Pro Asn  
 20 25 30  
 Pro Ser Leu Leu Phe Pro Val Ser Met Cys Ser Glu Arg Cys Ser  
 35 40 45  
 Glu Arg Cys Ser Cys Ser Pro Arg Leu Pro Pro His Pro Pro His  
 50 55 60  
 Phe Pro Pro Pro Gln Cys Val Ile Gly Val Leu Thr Pro Ser Ser  
 40 65 70 75  
 Thr Leu Ser Arg Phe Pro Pro Pro Glu Trp Asp Leu Leu Phe Pro  
 80 85 90  
 Arg Val Val Leu Ser Arg Gly Ala Ala Ala Gly Pro Pro Leu Val  
 45 95 100 105  
 Phe Leu Leu Glu Thr Gly Ala Phe Arg Glu Ser Ala Gly Ala Arg  
 110 115 120  
 50 Ala Asn Arg Ser Gln Arg Gly Val Ser Asp Thr Ser Pro Val Ser  
 125 130 135  
 His Gln Gly Glu Leu Ala Val Cys Asp Ala Val Thr Val Trp Val  
 55 140 145 150  
 Thr Asp Pro Trp Thr Ala Val Asp Leu Gly Val Leu Glu Val Glu  
 155 160 165  
 Val Leu Gly Glu Val Pro Ala Ala Gly Ser Ser Ser Leu Arg Gln  
 60 170 175 180  
 His Phe Phe Val Thr Arg Phe Glu Ala Asp Lys Ser Lys Glu Gly  
 185 190 195  
 65 Gly Pro Gly Val Gly Gly Gly Pro Ala Ala Gly Val Trp Thr Gly  
 200 205 210  
 Gly His Trp Val Ser Glu Cys Lys Ala Lys Gln Ser Tyr Gly Arg  
 215 220 225

-39-

Ala Leu Thr Thr Asp Ala Gln Gly Arg Val Asp Trp Arg Trp Ile  
 230 235 240  
 5 Gln Ile Gly Thr Ala Cys Val Cys Thr Leu Leu Ser Arg Thr Gly  
 245 250 255  
 Arg Ala  
 257

## 10 (2) INFORMATION FOR SEQ ID NO:11:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 971 bases  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

20 TTTGAACTCC TGACCTCAAG TCAAACACCG CCTCAGCCTC CCAAAGTGCT 50  
 GGGACCACAG GTGTGAGCCA TAGTGCCTGA CCTGTAGTTG TTGAATATTT 100  
 25 ATTATTAATC TACAAGTTGG GTGTGATGCA AGTCCCATAC ATGGAGTCCC 150  
 CCAAACCTTCT AGAGCAAGGG CTTCCTCCATA ATCCTGGCAG GCAGGCCTCC 200  
 CCTGGGGTTC CCAACTTCTG ACCTCACTGA AGTGTTTATC CTCTTCTCTA 250  
 35 ATCCCAGCCT CCTTTTCCCT GTTTCCATGT CCTCTGAGAG ATGCTCCCCG 300  
 TCCCCAGGC TCCCTCTGCA TCCCCCTCAT TTGCTTCCTC CCCAGTGTGT 350  
 40 CAATGGAGTC CTAACCCCA CCCTTGACAT TGTCCCCTTT TCCTCCTCCA 400  
 GAGTGGGACC TTATTTTCCC CCAAGTGGTC CTGTCTAGGG GTGCCGCTGC 450  
 CGGGCCCCCT CTGGTCTTCC TGCTGGAGAC TGGGGCCTTT TGGGAGTCAG 500  
 50 CAGGCACCCG GGCCAACCGC AGCCAGCGAG GGGTGAGCGA TACTTCACCG 550  
 GCGAGTCATC AGGGTGAGCT GGCCGTGTGC GATGCAGTCA GTGTCTGGGT 600  
 55 GACAGACCCC CGGACCGCTG TGGACTTGGT TGTGCTCGAG GTGGAGGTGT 650  
 TGGGTGAGGT GCCTGCAGCT GGCAGCAGTT CCCTCCACCA ACACTTCTTT 700  
 GTCACCTGCT TCAAGGCCGA TAACTCTGAA GAAGGTGGCC CAGGGGTAGG 750  
 65 TGGAGGGGCT GCCGCTGGGG TGTGGACCGG GGGGCACTGG GTGTCTGAGT 800  
 GCAAGGCCAA GCAGTCCTAT GTGCGGGCAT TGACCGCTGA TGCCAGGGC 850

-40-

CGTGTGGACT GCGATGGAT TCAAACTGGC ACAGCCTGTG TCTGCACACT 900

5 CCTCAGCCGG ACTGGCCGGG CCTGAGACTT ATACCCAGGA ACTGGTCAGG 950

CAGAAAAAGA ACAGAGCTAG G 971

10

## (2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 186 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

15

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

20

Pro Pro Pro Leu Thr Leu Ser Pro Phe Pro Pro Pro Glu Trp Asp  
 1 5 10 15

25

Leu Ile Phe Pro Gln Val Val Leu Ser Arg Gly Ala Ala Ala Gly  
 20 25 30

Pro Pro Leu Val Phe Leu Leu Glu Thr Gly Ala Phe Trp Glu Ser  
 35 40 45

30

Ala Gly Thr Arg Ala Asn Arg Ser Gln Arg Gly Val Ser Asp Thr  
 50 55 60

Ser Pro Ala Ser His Gln Gly Glu Leu Ala Val Cys Asp Ala Val  
 65 70 75

35

Ser Val Trp Val Thr Asp Pro Arg Thr Ala Val Asp Leu Val Val  
 80 85 90

40

Leu Glu Val Glu Val Leu Gly Glu Val Pro Ala Ala Gly Ser Ser  
 95 100 105

Ser Leu His Gln His Phe Phe Val Thr Cys Phe Lys Ala Asp Asn  
 110 115 120

45

Ser Glu Glu Gly Gly Pro Gly Val Gly Gly Gly Ala Ala Ala Gly  
 125 130 135

Val Trp Thr Gly Gly His Trp Val Ser Glu Cys Lys Ala Lys Gln  
 140 145 150

50

Ser Tyr Val Arg Ala Leu Thr Ala Asp Ala Gln Gly Arg Val Asp  
 155 160 165

55

Trp Arg Trp Ile Gln Thr Gly Thr Ala Cys Val Cys Thr Leu Leu  
 170 175 180

Ser Arg Thr Gly Arg Ala  
 185 186

60

## (2) INFORMATION FOR SEQ ID NO:13:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 130 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

65

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Gly Val Ser Glu Thr Ala Pro Ala Ser Arg Arg Gly Glu Leu Ala

-41-

```

      1           5           10           15
Val Cys Asp Ala Val Ser Gly Trp Val Thr Asp Arg Arg Thr Ala
      20           25           30
5 Val Asp Leu Arg Gly Arg Glu Val Glu Val Leu Gly Glu Val Pro
      35           40           45
Ala Ala Gly Gly Ser Pro Leu Arg Gln Tyr Phe Phe Glu Thr Arg
      50           55           60
10 Cys Lys Ala Asp Asn Ala Glu Glu Gly Gly Pro Gly Ala Gly Gly
      65           70           75
15 Gly Gly Lys Arg Gly Val Asp Arg Arg His Trp Val Ser Glu Cys
      80           85           90
Lys Ala Lys Gln Ser Tyr Val Arg Ala Leu Thr Ala Asp Ala Gln
      95           100          105
20 Gly Arg Val Gly Trp Arg Trp Ile Arg Ile Asp Thr Ala Cys Val
      110          115          120
25 Cys Thr Leu Leu Ser Arg Thr Gly Arg Ala
      125          130

```

## (2) INFORMATION FOR SEQ ID NO:14:

```

30 (i) SEQUENCE CHARACTERISTICS:
      (A) LENGTH: 130 amino acids
      (B) TYPE: amino acid
      (D) TOPOLOGY: linear

```

```

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

```

```

Gly Val Ser Glu Thr Ala Pro Ala Ser Arg Arg Gly Glu Leu Ala
  1           5           10           15
40 Val Cys Asp Ala Val Ser Gly Trp Val Thr Asp Arg Arg Thr Ala
      20           25           30
Val Asp Leu Arg Gly Arg Glu Val Glu Val Leu Gly Glu Val Pro
      35           40           45
45 Ala Ala Gly Gly Ser Pro Leu Arg Gln Tyr Phe Phe Glu Thr Arg
      50           55           60
Cys Lys Ala Asp Asn Ala Glu Glu Gly Gly Pro Gly Ala Gly Gly
      65           70           75
50 Gly Gly His Arg Gly Val Asp Arg Arg His Trp Val Ser Glu Cys
      80           85           90
Lys Ala Lys Gln Ser Tyr Val Arg Ala Leu Thr Ala Asp Ala Gln
      95           100          105
55 Gly Arg Val Gly Trp Arg Trp Ile Arg Ile Asp Thr Ala Cys Val
      110          115          120
60 Cys Thr Leu Leu Ser Arg Thr Gly Arg Ala
      125          130

```

## (2) INFORMATION FOR SEQ ID NO:15:

```

65 (i) SEQUENCE CHARACTERISTICS:
      (A) LENGTH: 130 amino acids
      (B) TYPE: amino acid
      (D) TOPOLOGY: linear

```

-42-

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

5 Gly Val Ser Glu Thr Ala Pro Ala Ser Arg Arg Gly Glu Leu Ala  
 1 5 10 15  
 Val Cys Asp Ala Val Ser Gly Trp Val Thr Asp Arg Arg Thr Ala  
 20 25 30  
 10 Val Asp Leu Arg Gly Arg Glu Val Glu Val Leu Gly Glu Val Pro  
 35 40 45  
 Ala Ala Gly Gly Ser Pro Leu Arg Gln Tyr Phe Phe Glu Thr Arg  
 50 55 60  
 15 Cys Lys Ala Asp Asn Ala Glu Glu Gly Gly Pro Gly Ala Gly Gly  
 65 70 75  
 Gly Gly Gln Arg Gly Val Asp Arg Arg His Trp Val Ser Glu Cys  
 80 85 90  
 20 Lys Ala Lys Gln Ser Tyr Val Arg Ala Leu Thr Ala Asp Ala Gln  
 95 100 105  
 25 Gly Arg Val Gly Trp Arg Trp Ile Arg Ile Asp Thr Ala Cys Val  
 110 115 120  
 Cys Thr Leu Leu Ser Arg Thr Gly Arg Ala  
 125 130

## (2) INFORMATION FOR SEQ ID NO:16:

## (i) SEQUENCE CHARACTERISTICS:

- 35 (A) LENGTH: 130 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

40 Gly Val Ser Glu Thr Ala Pro Ala Ser Arg Arg Gly Glu Leu Ala  
 1 5 10 15  
 Val Cys Asp Ala Val Ser Gly Trp Val Thr Asp Arg Arg Thr Ala  
 20 25 30  
 45 Val Asp Leu Arg Gly Arg Glu Val Glu Val Leu Gly Glu Val Pro  
 35 40 45  
 Ala Ala Gly Gly Ser Pro Leu Arg Gln Tyr Phe Phe Glu Thr Arg  
 50 55 60  
 50 Cys Lys Ala Asp Asn Ala Glu Glu Gly Gly Pro Gly Ala Gly Gly  
 65 70 75  
 55 Gly Gly Arg Arg Gly Val Asp Arg Arg His Trp Val Ser Glu Cys  
 80 85 90  
 Lys Ala Lys Gln Ser Tyr Val Arg Ala Leu Thr Ala Asp Ala Gln  
 95 100 105  
 60 Gly Arg Val Gly Trp Arg Trp Ile Arg Ile Asp Thr Ala Cys Val  
 110 115 120  
 Cys Thr Leu Leu Ser Arg Thr Gly Arg Ala  
 125 130

## (2) INFORMATION FOR SEQ ID NO:17:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 130 amino acids



-43-

(B) TYPE: amino acid  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

5 Gly Val Ser Glu Thr Ala Pro Ala Ser Arg Arg Gly Glu Leu Ala  
1 5 10 15  
10 Val Cys Asp Ala Val Ser Gly Trp Val Thr Asp Arg Arg Thr Ala  
20 25 30  
Val Asp Leu Arg Gly Arg Glu Val Glu Val Leu Gly Glu Val Pro  
35 40 45  
15 Ala Ala Gly Gly Ser Pro Leu Arg Gln Tyr Phe Phe Glu Thr Arg  
50 55 60  
Cys Lys Ala Asp Asn Ala Glu Glu Gly Gly Pro Gly Ala Gly Gly  
65 70 75  
20 Gly Gly Cys Arg Gly Val Asp Arg Arg Glu Trp Val Ser Glu Cys  
80 85 90  
Lys Ala Lys Gln Ser Tyr Val Arg Ala Leu Thr Ala Asp Ala Gln  
25 95 100 105  
Gly Arg Val Gly Trp Arg Trp Ile Arg Ile Asp Thr Ala Cys Val  
110 115 120  
30 Cys Thr Leu Leu Ser Arg Thr Gly Arg Ala  
125 130

## (2) INFORMATION FOR SEQ ID NO:18:

35 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 130 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

Gly Val Ser Glu Thr Ala Pro Ala Ser Arg Arg Gly Glu Leu Ala  
1 5 10 15  
45 Val Cys Asp Ala Val Ser Gly Trp Val Thr Asp Arg Arg Thr Ala  
20 25 30  
Val Asp Leu Arg Gly Arg Glu Val Glu Val Leu Gly Glu Val Pro  
35 40 45  
50 Ala Ala Gly Gly Ser Pro Leu Arg Gln Tyr Phe Phe Glu Thr Arg  
50 55 60  
Cys Lys Ala Asp Asn Ala Glu Glu Gly Gly Pro Gly Ala Gly Gly  
65 70 75  
Gly Gly Cys Arg Gly Val Asp Arg Arg Phe Trp Val Ser Glu Cys  
80 85 90  
60 Lys Ala Lys Gln Ser Tyr Val Arg Ala Leu Thr Ala Asp Ala Gln  
95 100 105  
Gly Arg Val Gly Trp Arg Trp Ile Arg Ile Asp Thr Ala Cys Val  
110 115 120  
65 Cys Thr Leu Leu Ser Arg Thr Gly Arg Ala  
125 130

## (2) INFORMATION FOR SEQ ID NO:19:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 130 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

Gly Val Ser Glu Thr Ala Pro Ala Ser Arg Arg Gly Glu Leu Ala  
 1 5 10 15  
 Val Cys Asp Ala Val Ser Gly Trp Val Thr Asp Arg Arg Thr Ala  
 20 25 30  
 Val Asp Leu Arg Gly Arg Glu Val Glu Val Leu Gly Glu Val Pro  
 15 35 40 45  
 Ala Ala Gly Gly Ser Pro Leu Arg Gln Tyr Phe Phe Glu Thr Arg  
 50 55 60  
 Cys Lys Ala Asp Asn Ala Glu Glu Gly Gly Pro Gly Ala Gly Gly  
 20 65 70 75  
 Gly Gly Cys Arg Gly Val Asp Arg Arg Pro Trp Val Ser Glu Cys  
 80 85 90  
 Lys Ala Lys Gln Ser Tyr Val Arg Ala Leu Thr Ala Asp Ala Gln  
 25 95 100 105  
 Gly Arg Val Gly Trp Arg Trp Ile Arg Ile Asp Thr Ala Cys Val  
 30 110 115 120  
 Cys Thr Leu Leu Ser Arg Thr Gly Arg Ala  
 125 130

35 (2) INFORMATION FOR SEQ ID NO:20:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 130 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

Gly Val Ser Glu Thr Ala Pro Ala Ser Arg Arg Gly Glu Leu Ala  
 45 1 5 10 15  
 Val Cys Asp Ala Val Ser Gly Trp Val Thr Asp Arg Arg Thr Ala  
 20 25 30  
 Val Asp Leu Arg Gly Arg Glu Val Glu Val Leu Gly Glu Val Pro  
 50 35 40 45  
 Ala Ala Gly Gly Ser Pro Leu Arg Gln Tyr Phe Phe Glu Thr Arg  
 55 50 55 60  
 Cys Lys Ala Asp Asn Ala Glu Glu Gly Gly Pro Gly Ala Gly Gly  
 65 65 70 75  
 Gly Gly Cys Arg Gly Val Asp Arg Arg Tyr Trp Val Ser Glu Cys  
 80 85 90  
 Lys Ala Lys Gln Ser Tyr Val Arg Ala Leu Thr Ala Asp Ala Gln  
 95 100 105  
 Gly Arg Val Gly Trp Arg Trp Ile Arg Ile Asp Thr Ala Cys Val  
 65 110 115 120  
 Cys Thr Leu Leu Ser Arg Thr Gly Arg Ala  
 125 130

-45-

## (2) INFORMATION FOR SEQ ID NO:21:

## (i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 130 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

10 Gly Val Ser Glu Thr Ala Pro Ala Ser Arg Arg Gly Glu Leu Ala  
1 5 10 15  
Val Cys Asp Ala Val Ser Gly Trp Val Thr Asp Arg Arg Thr Ala  
20 25 30  
15 Val Asp Leu Arg Gly Arg Glu Val Glu Val Leu Gly Glu Val Pro  
35 40 45  
20 Ala Ala Gly Gly Ser Pro Leu Arg Gln Tyr Phe Phe Glu Thr Arg  
50 55 60  
Cys Lys Ala Asp Asn Ala Glu Glu Gly Gly Pro Gly Ala Gly Gly  
65 70 75  
25 Gly Gly Cys Arg Gly Val Asp Arg Arg Trp Trp Val Ser Glu Cys  
80 85 90  
Lys Ala Lys Gln Ser Tyr Val Arg Ala Leu Thr Ala Asp Ala Gln  
95 100 105  
30 Gly Arg Val Gly Trp Arg Trp Ile Arg Ile Asp Thr Ala Cys Val  
110 115 120  
35 Cys Thr Leu Leu Ser Arg Thr Gly Arg Ala  
125 130

## (2) INFORMATION FOR SEQ ID NO:22:

## (i) SEQUENCE CHARACTERISTICS:

- 40 (A) LENGTH: 130 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

45 Gly Val Ser Glu Thr Ala Pro Ala Ser Arg Arg Gly Glu Leu Ala  
1 5 10 15  
Val Cys Asp Ala Val Ser Gly Trp Val Thr Asp Arg Arg Thr Ala  
20 25 30  
50 Val Asp Leu Arg Gly Arg Glu Val Glu Val Leu Gly Glu Val Pro  
35 40 45  
55 Ala Ala Gly Gly Ser Pro Leu Arg Gln Tyr Phe Phe Glu Thr Arg  
50 55 60  
Cys Lys Ala Asp Asn Ala Ser Glu Gly Gly Pro Gly Ala Gly Gly  
65 70 75  
60 Gly Gly Cys Arg Gly Val Asp Arg Arg His Trp Val Ser Glu Cys  
80 85 90  
Lys Ala Lys Gln Ser Tyr Val Arg Ala Leu Thr Ala Asp Ala Gln  
95 100 105  
65 Gly Arg Val Gly Trp Arg Trp Ile Arg Ile Asp Thr Ala Cys Val  
110 115 120

-46-

Cys Thr Leu Leu Ser Arg Thr Gly Arg Ala  
125 130

5 (2) INFORMATION FOR SEQ ID NO:23:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 130 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

Gly Val Ser Glu Thr Ala Pro Ala Ser Arg Arg Gly Glu Leu Ala  
1 5 10 15  
 Val Cys Asp Ala Val Ser Gly Trp Val Thr Asp Arg Arg Thr Ala  
20 25 30  
 Val Asp Leu Arg Gly Arg Glu Val Glu Val Leu Gly Glu Val Pro  
35 40 45  
 Ala Ala Gly Gly Ser Pro Leu Arg Gln Tyr Phe Phe Glu Thr Arg  
50 55 60  
 Cys Lys Ala Asp Asn Ala Thr Glu Gly Gly Pro Gly Ala Gly Gly  
65 70 75  
 Gly Gly Cys Arg Gly Val Asp Arg Arg His Trp Val Ser Glu Cys  
80 85 90  
 Lys Ala Lys Gln Ser Tyr Val Arg Ala Leu Thr Ala Asp Ala Gln  
95 100 105  
 Gly Arg Val Gly Trp Arg Trp Ile Arg Ile Asp Thr Ala Cys Val  
110 115 120  
 Cys Thr Leu Leu Ser Arg Thr Gly Arg Ala  
125 130

40 (2) INFORMATION FOR SEQ ID NO:24:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 12 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

Arg Arg His Trp Val Ser Glu Cys Lys Ala Lys Gln  
1 5 10 12

(2) INFORMATION FOR SEQ ID NO:25:

- 55 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 61 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

60

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

Gly Val Ser Glu Thr Ala Pro Ala Ser Arg Arg Gly Glu Leu Ala  
1 5 10 15  
 Val Cys Asp Ala Val Ser Gly Trp Val Thr Asp Arg Arg Thr Ala  
20 25 30  
 Val Asp Leu Arg Gly Arg Glu Val Glu Val Leu Gly Glu Val Pro  
35 40 45

-47-

Cys  
61

10 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 17 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

15 Gly Val Ser Glu Thr Ala Pro Ala Ser Arg Gly Glu Leu Ala  
1 5 10 15

25 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 45 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

30 Cys Asp Ala Val Ser Gly Trp Val Thr Asp Arg Arg Thr Ala Val  
1 5 10 15

Ala Gly Gly Ser Pro Leu Arg Gln Tyr Phe Phe Glu Thr Arg Cys  
35 40 45

45 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 62 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

50      Cys Asp Ala Val Ser Gly Trp Val Thr Asp Arg Arg Thr Ala Val  
              1                      5                      10                      15

55 Ala Gly Gly Ser Pro<sub>35</sub> Leu Arg Gln Tyr Phe<sub>40</sub> Phe Glu Thr Arg Cys<sub>45</sub>

Gly Cys  
62

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 74 amino acids  
(B) TYPE: amino acid

-48-

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

5 Cys Asp Ala Val Ser Gly Trp Val Thr Asp Arg Arg Thr Ala Val  
1 5 10 15  
Asp Leu Arg Gly Arg Glu Val Glu Val Leu Gly Glu Val Pro Ala  
20 25 30  
10 Ala Gly Gly Ser Pro Leu Arg Gln Tyr Phe Phe Glu Thr Arg Cys  
35 40 45  
15 Lys Ala Asp Asn Ala Glu Glu Gly Gly Pro Gly Ala Gly Gly Gly  
50 55 60  
Gly Cys Arg Gly Val Asp Arg Arg His Trp Val Ser Glu Cys  
65 70 74

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 103 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

30 Cys Asp Ala Val Ser Gly Trp Val Thr Asp Arg Arg Thr Ala Val  
1 5 10 15  
Asp Leu Arg Gly Arg Glu Val Glu Val Leu Gly Glu Val Pro Ala  
20 25 30  
35 Ala Gly Gly Ser Pro Leu Arg Gln Tyr Phe Phe Glu Thr Arg Cys  
35 40 45  
Lys Ala Asp Asn Ala Glu Glu Gly Gly Pro Gly Ala Gly Gly Gly  
50 55 60  
40 Gly Cys Arg Gly Val Asp Arg Arg His Trp Val Ser Glu Cys Lys  
65 70 75  
45 Ala Lys Gln Ser Tyr Val Arg Ala Leu Thr Ala Asp Ala Gln Gly  
80 85 90  
Arg Val Gly Trp Arg Trp Ile Arg Ile Asp Thr Ala Cys  
95 100 103

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 105 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

60 Cys Asp Ala Val Ser Gly Trp Val Thr Asp Arg Arg Thr Ala Val  
1 5 10 15  
Asp Leu Arg Gly Arg Glu Val Glu Val Leu Gly Glu Val Pro Ala  
20 25 30  
65 Ala Gly Gly Ser Pro Leu Arg Gln Tyr Phe Phe Glu Thr Arg Cys  
35 40 45  
Lys Ala Asp Asn Ala Glu Glu Gly Gly Pro Gly Ala Gly Gly Gly  
50 55 60

-49-

Gly Cys Arg Gly Val Asp Arg Arg His Trp Val Ser Glu Cys Lys  
                                 65                                70                                75  
 5   Ala Lys Gln Ser Tyr Val Arg Ala Leu Thr Ala Asp Ala Gln Gly  
                                 80                                85                                90  
   Arg Val Gly Trp Arg Trp Ile Arg Ile Asp Thr Ala Cys Val Cys  
                                 95                                100                                105

10   (2) INFORMATION FOR SEQ ID NO:32:

      (i) SEQUENCE CHARACTERISTICS:  
           (A) LENGTH: 17 amino acids  
 15        (B) TYPE: amino acid  
           (D) TOPOLOGY: linear

      (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

20   Arg Gly Glu Leu Ala Val Cys Asp Ala Val Ser Gly Trp Val Thr  
       1                                5                                10                                15  
   Asp Arg  
       17

25   (2) INFORMATION FOR SEQ ID NO:33:

      (i) SEQUENCE CHARACTERISTICS:  
           (A) LENGTH: 24 amino acids  
 30        (B) TYPE: amino acid  
           (D) TOPOLOGY: linear

      (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

35   Arg Gly Glu Leu Ala Val Cys Asp Ala Val Ser Gly Trp Val Thr  
       1                                5                                10                                15  
   Asp Arg Arg Thr Ala Val Asp Leu Arg  
                                 20                                24

40   (2) INFORMATION FOR SEQ ID NO:34:

      (i) SEQUENCE CHARACTERISTICS:  
           (A) LENGTH: 20 amino acids  
 45        (B) TYPE: amino acid  
           (D) TOPOLOGY: linear

      (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

50   Arg Gly Arg Glu Val Glu Val Leu Gly Glu Val Pro Ala Ala Gly  
       1                                5                                10                                15  
   Gly Ser Pro Leu Arg  
                                 20

55   (2) INFORMATION FOR SEQ ID NO:35:

      (i) SEQUENCE CHARACTERISTICS:  
           (A) LENGTH: 18 amino acids  
 60        (B) TYPE: amino acid  
           (D) TOPOLOGY: linear

      (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

65   Cys Lys Ala Asp Asn Ala Glu Glu Gly Gly Pro Gly Ala Gly Gly  
       1                                5                                10                                15  
   Gly Gly Cys  
                                 18

-50-

## (2) INFORMATION FOR SEQ ID NO:36:

## (i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 9 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

10 Arg Gln Tyr Phe Phe Glu Thr Arg Cys  
1 5 9

## (2) INFORMATION FOR SEQ ID NO:37:

## (i) SEQUENCE CHARACTERISTICS:

- 15 (A) LENGTH: 59 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

20 Cys Lys Ala Asp Asn Ala Glu Glu Gly Gly Pro Gly Ala Gly Gly  
1 5 10 15  
25 Gly Gly Cys Arg Gly Val Asp Arg Arg His Trp Val Ser Glu Cys  
20 25 30  
30 Lys Ala Lys Gln Ser Tyr Val Arg Ala Leu Thr Ala Asp Ala Gln  
35 40 45  
30 Gly Arg Val Gly Trp Arg Trp Ile Arg Ile Asp Thr Ala Cys  
50 55 59

## (2) INFORMATION FOR SEQ ID NO:38:

## (i) SEQUENCE CHARACTERISTICS:

- 35 (A) LENGTH: 18 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

40 Cys Lys Ala Asp Asn Ala Glu Glu Gly Gly Pro Gly Ala Gly Gly  
1 5 10 15  
45 Gly Gly Cys  
18

## (2) INFORMATION FOR SEQ ID NO:39:

## (i) SEQUENCE CHARACTERISTICS:

- 50 (A) LENGTH: 42 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

60 Cys Arg Gly Val Asp Arg Arg His Trp Val Ser Glu Cys Lys Ala  
1 5 10 15  
Lys Gln Ser Tyr Val Arg Ala Leu Thr Ala Asp Ala Gln Gly Arg  
20 25 30  
65 Val Gly Trp Arg Trp Ile Arg Ile Asp Thr Ala Cys  
35 40 42

## (2) INFORMATION FOR SEQ ID NO:40:

## (i) SEQUENCE CHARACTERISTICS:



-51-

(A) LENGTH: 30 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

Cys Lys Ala Asp Asn Ala Glu Glu Gly Gly Pro Gly Ala Gly Gly  
 1 5 10 15

10 Gly Gly Cys Arg Gly Val Asp Arg Arg His Trp Val Ser Glu Cys  
 20 25 30

15 (2) INFORMATION FOR SEQ ID NO:41:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 19 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

Arg Cys Lys Ala Asp Asn Ala Glu Glu Gly Gly Pro Gly Ala Gly  
 1 5 10 15

25 Gly Gly Gly Cys  
 19

30 (2) INFORMATION FOR SEQ ID NO:42:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 58 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

Lys Ala Asp Asn Ala Glu Glu Gly Gly Pro Gly Ala Gly Gly Gly  
 1 5 10 15

40 Gly Cys Arg Gly Val Asp Arg Arg His Trp Val Ser Glu Cys Lys  
 20 25 30

45 Ala Lys Gln Ser Tyr Val Arg Ala Leu Thr Ala Asp Ala Gln Gly  
 35 40 45

Arg Val Gly Trp Arg Trp Ile Arg Ile Asp Thr Ala Cys  
 50 55 58

50 (2) INFORMATION FOR SEQ ID NO:43:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 30 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

55 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

Lys Ala Asp Asn Ala Glu Glu Gly Gly Pro Gly Ala Gly Gly Gly  
 1 5 10 15

60 Gly Cys Arg Gly Val Asp Arg Arg His Trp Val Ser Glu Cys Lys  
 20 25 30

65 (2) INFORMATION FOR SEQ ID NO:44:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 20 amino acids

-52-

(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

5 Arg Gly Val Asp Arg Arg His Trp Val Ser Glu Cys Lys Ala Lys  
1 5 10 15  
10 Gln Ser Tyr Val Arg  
20

(2) INFORMATION FOR SEQ ID NO:45:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 11 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

20 Arg Arg His Trp Val Ser Glu Cys Lys Ala Lys  
1 5 10 11

(2) INFORMATION FOR SEQ ID NO:46:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 11 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

35 Thr Ala Asp Ala Gln Gly Arg Val Gly Trp Arg  
1 5 10 11

(2) INFORMATION FOR SEQ ID NO:47:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 130 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

45 Gly Val Ser Glu Thr Ala Pro Ala Ser Arg Arg Gly Glu Leu Ala  
1 5 10 15  
Val Cys Asp Ala Val Ser Gly Trp Val Thr Asp Arg Arg Thr Ala  
20 25 30  
50 Val Asp Leu Arg Gly Arg Glu Val Glu Val Leu Gly Glu Val Pro  
35 40 45  
55 Ala Ala Gly Gly Ser Pro Leu Arg Gln Tyr Phe Phe Glu Thr Arg  
50 55 60  
Cys Lys Ala Asp Asn Ala Glu Glu Gly Gly Pro Gly Ala Gly Gly  
65 70 75  
60 Gly Gly Cys Arg Gly Val Asp Arg Arg His Trp Val Ser Glu Cys  
80 85 90  
Lys Ala Lys Gln Ser Tyr Val Arg Ala Leu Thr Ala Asp Ala Gln  
95 100 105  
65 Gly Arg Val Gly Trp Arg Trp Ile Arg Ile Asp Thr Ala Cys Val  
110 115 120  
Cys Val Leu Thr Val Lys Arg Val Arg Arg

-53-

125

130

## (2) INFORMATION FOR SEQ ID NO:48:

- 5 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 91 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

## 10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

Val Leu Gly Glu Val Pro Ala Ala Gly Gly Ser Pro Leu Arg Gln  
 1 5 10 15  
 Tyr Phe Phe Glu Thr Arg Cys Lys Ala Asp Asn Ala Glu Glu Gly  
 20 25 30  
 Gly Pro Gly Ala Gly Gly Gly Gly Cys Arg Gly Val Asp Arg Arg  
 35 40 45  
 His Trp Val Ser Glu Cys Lys Ala Lys Gln Ser Tyr Val Arg Ala  
 50 55 60  
 Leu Thr Ala Asp Ala Gln Gly Arg Val Gly Trp Arg Trp Ile Arg  
 65 70 75  
 Ile Asp Thr Ala Cys Val Cys Val Leu Thr Val Lys Arg Val Arg  
 80 85 90  
 Arg  
 91

## (2) INFORMATION FOR SEQ ID NO:49:

- 35 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 91 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

## 40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:

Val Leu Gly Glu Val Pro Ala Ala Gly Gly Ser Pro Leu Arg Gln  
 1 5 10 15  
 Tyr Phe Phe Glu Thr Arg Cys Lys Ala Asp Asn Ala Glu Glu Gly  
 20 25 30  
 Gly Pro Gly Ala Gly Gly Gly Gly Cys Arg Gly Val Asp Arg Arg  
 35 40 45  
 His Trp Val Ser Glu Cys Lys Ala Lys Gln Ser Tyr Val Arg Ala  
 50 55 60  
 Leu Thr Ala Asp Ala Gln Gly Arg Val Gly Trp Arg Trp Ile Arg  
 65 70 75  
 Ile Asp Thr Ala Cys Val Cys Ser Leu Thr Ile Lys Arg Ile Arg  
 80 85 90  
 Ala  
 91

## (2) INFORMATION FOR SEQ ID NO:50:

- 65 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 92 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

-54-

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

5 Val Leu Gly Glu Val Pro Ala Ala Gly Gly Ser Pro Leu Arg Gln  
 1 5 10 15  
 Tyr Phe Phe Glu Thr Arg Cys Lys Ala Asp Asn Ala Glu Glu Gly  
 20 25 30  
 10 Gly Pro Gly Ala Gly Gly Gly Gly Cys Arg Gly Val Asp Arg Arg  
 35 40 45  
 His Trp Val Ser Glu Cys Lys Ala Lys Gln Ser Tyr Val Arg Ala  
 50 55 60  
 15 Leu Thr Ala Asp Ala Gln Gly Arg Val Gly Trp Arg Trp Ile Arg  
 65 70 75  
 Ile Asp Thr Ala Cys Val Cys Thr Leu Ser Arg Lys Ala Gly Arg  
 80 85 90  
 20 Arg Ala  
 92

## (2) INFORMATION FOR SEQ ID NO:51:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 132 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:

35 Asp Asp Asp Ser Pro Ile Ala Arg Arg Gly Glu Ile Ser Val Cys  
 1 5 10 15  
 Asp Ser Val Ser Asp Trp Val Ser Ala Pro Asp Lys Asp Thr Ala  
 20 25 30  
 40 Val Asp Ile Lys Gly Asp Asp Val Met Val Leu Lys Lys Val Gly  
 35 40 45  
 Ile Asn His Ser Val Val Leu Gly Glu Val Pro Ala Ala Gly Gly  
 50 55 60  
 45 Ser Pro Leu Arg Gln Tyr Phe Phe Glu Thr Arg Cys Lys Ala Asp  
 65 70 75  
 Asn Ala Glu Glu Gly Gly Pro Gly Ala Gly Gly Gly Gly Cys Arg  
 80 85 90  
 50 Gly Val Asp Arg Arg His Trp Val Ser Glu Cys Lys Ala Lys Gln  
 95 100 105  
 55 Ser Tyr Val Arg Ala Leu Thr Ala Asp Ala Gln Gly Arg Val Gly  
 110 115 120  
 Trp Arg Trp Ile Arg Ile Asp Thr Ala Cys Val Cys  
 125 130 132

## (2) INFORMATION FOR SEQ ID NO:52:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 142 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:

Ser Ser Ser His Pro Ile Phe His Arg Gly Glu Phe Ser Val Cys

-55-

30 (2) INFORMATION FOR SEQ ID NO:53:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

65 (2) INFORMATION FOR SEQ ID NO:54:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 129 amino acids

-56-

(B) TYPE: amino acid

(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:

5 Gly Val Ser Glu Thr Ala Pro Ala Ser Arg Arg Gly Glu Leu Ala  
1 5 10 15

10 Val Cys Asp Ala Val Ser Gly Trp Val Thr Asp Arg Arg Thr Ala  
20 25 30

Val Asp Leu Arg Gly Arg Glu Val Glu Val Leu Gly Glu Val Pro  
35 40 45

15 Ala Ala Gly Gly Ser Pro Leu Arg Gln Tyr Phe Phe Glu Thr Arg  
50 55 60

Lys Ala Asp Asn Ala Glu Glu Gly Gly Pro Gly Ala Gly Gly Gly  
65 70 75

20 Gly Cys Arg Gly Val Asp Arg Arg His Trp Val Ser Glu Cys Lys  
80 85 90

25 Ala Lys Gln Ser Tyr Val Arg Ala Leu Thr Ala Asp Ala Gln Gly  
95 100 105

Arg Val Gly Trp Arg Trp Ile Arg Ile Asp Thr Ala Cys Val Cys  
110 115 120

30 Thr Leu Leu Ser Arg Thr Gly Arg Ala  
125 129

## (2) INFORMATION FOR SEQ ID NO:55:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 124 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:

40 Gly Val Ser Glu Thr Ala Pro Ala Ser Arg Arg Gly Glu Leu Ala  
1 5 10 15

45 Val Cys Asp Ala Val Ser Gly Trp Val Thr Asp Arg Arg Thr Ala  
20 25 30

Val Asp Leu Arg Gly Arg Glu Val Glu Val Leu Gly Glu Val Pro  
35 40 45

50 Ala Ala Gly Gly Ser Pro Leu Arg Arg Cys Lys Ala Asp Asn Ala  
50 55 60

55 Glu Glu Gly Gly Pro Gly Ala Gly Gly Gly Gly Cys Arg Gly Val  
65 70 75

Asp Arg Arg His Trp Val Ser Glu Cys Lys Ala Lys Gln Ser Tyr  
80 85 90

60 Val Arg Ala Leu Thr Ala Asp Ala Gln Gly Arg Val Gly Trp Arg  
95 100 105

Trp Ile Arg Ile Asp Thr Ala Cys Val Cys Thr Leu Leu Ser Arg  
110 115 120

65 Thr Gly Arg Ala  
124

## (2) INFORMATION FOR SEQ ID NO:56:

-57-

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 107 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

Gly Val Ser Glu Thr Ala Pro Ala Ser Arg Arg Gly Glu Leu Ala  
 1 5 10 15  
 10 Val Cys Asp Ala Val Ser Gly Trp Val Thr Asp Arg Arg Thr Ala  
 20 25 30  
 15 Val Asp Leu Arg Gly Arg Glu Val Glu Val Leu Gly Glu Val Pro  
 35 40 45  
 Ala Ala Gly Gly Ser Pro Leu Arg Gln Tyr Phe Phe Glu Thr Arg  
 50 55 60  
 20 Arg His Trp Val Ser Glu Cys Lys Ala Lys Gln Ser Tyr Val Arg  
 65 70 75  
 Ala Leu Thr Ala Asp Ala Gln Gly Arg Val Gly Trp Arg Trp Ile  
 80 85 90  
 25 Arg Ile Asp Thr Ala Cys Val Cys Thr Leu Leu Ser Arg Thr Gly  
 95 100 105  
 Arg Ala  
 107

30

(2) INFORMATION FOR SEQ ID NO:57:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 126 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:

Gly Val Ser Glu Thr Ala Pro Ala Ser Arg Arg Gly Glu Leu Ala  
 1 5 10 15  
 40 Val Cys Asp Ala Val Ser Gly Trp Val Thr Asp Arg Arg Thr Ala  
 20 25 30  
 45 Val Asp Leu Arg Gly Arg Glu Val Glu Val Leu Gly Glu Val Pro  
 35 40 45  
 50 Ala Ala Gly Gly Ser Pro Leu Arg Gln Tyr Phe Phe Glu Thr Arg  
 50 55 60  
 Cys Lys Ala Asp Asn Ala Glu Glu Gly Gly Pro Gly Ala Gly Gly  
 65 70 75  
 55 Gly Gly Cys Arg Gly Val Asp Arg Arg Glu Cys Lys Ala Lys Gln  
 80 85 90  
 60 Ser Tyr Val Arg Ala Leu Thr Ala Asp Ala Gln Gly Arg Val Gly  
 95 100 105  
 Trp Arg Trp Ile Arg Ile Asp Thr Ala Cys Val Cys Thr Leu Leu  
 110 115 120  
 65 Ser Arg Thr Gly Arg Ala  
 125 126

65

(2) INFORMATION FOR SEQ ID NO:58:

-58-

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 114 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:

10 Gly Val Ser Glu Thr Ala Pro Ala Ser Arg Arg Gly Glu Leu Ala  
     1                    5                    10                    15  
 20 Val Cys Asp Ala Val Ser Gly Trp Val Thr Asp Arg Arg Thr Ala  
     20                    25                    30  
 15 Val Asp Leu Arg Gly Arg Glu Val Glu Val Leu Gly Glu Val Pro  
     35                    40                    45  
 20 Ala Ala Gly Gly Ser Pro Leu Arg Gln Tyr Phe Phe Glu Thr Arg  
     50                    55                    60  
 25 Cys Lys Ala Asp Asn Ala Glu Glu Gly Gly Pro Gly Ala Gly Gly  
     65                    70                    75  
 30 Gly Gly Cys Arg Gly Val Asp Arg Arg His Ala Asp Ala Gln Gly  
     80                    85                    90  
 35 Arg Val Gly Trp Arg Trp Ile Arg Ile Asp Thr Ala Cys Val Cys  
     95                    100                    105  
 40 Thr Leu Leu Ser Arg Thr Gly Arg Ala  
     110                    114

(2) INFORMATION FOR SEQ ID NO:59:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 130 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:

40 Gly Val Ser Glu Thr Ala Pro Ala Ser Arg Arg Gly Glu Leu Ala  
     1                    5                    10                    15  
 45 Val Cys Asp Ala Val Ser Gly Trp Val Thr Asp Arg Arg Thr Ala  
     20                    25                    30  
 50 Val Asp Leu Arg Gly Arg Glu Val Glu Val Leu Gly Glu Val Pro  
     35                    40                    45  
 55 Ala Ala Gly Gly Ser Pro Leu His Gln Tyr Phe Phe Glu Thr Arg  
     50                    55                    60  
 60 Cys Lys Ala Asp Asn Ala Glu Glu Gly Gly Pro Gly Ala Gly Gly  
     65                    70                    75  
 65 Gly Gly Cys Arg Gly Val Asp Arg Arg His Trp Val Ser Glu Cys  
     80                    85                    90  
 70 Lys Ala Lys Gln Ser Tyr Val Arg Ala Leu Thr Ala Asp Ala Gln  
     95                    100                    105  
 75 Gly Arg Val Gly Trp Arg Trp Ile Arg Ile Asp Thr Ala Cys Val  
     110                    115                    120  
 80 Cys Thr Leu Leu Ser Arg Thr Gly Arg Ala  
     125                    130

(2) INFORMATION FOR SEQ ID NO:60:



-59-

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 130 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:

Gly Val Ser Glu Thr Ala Pro Ala Ser Arg Arg Gly Glu Leu Ala  
 1 5 10 15  
 Val Cys Asp Ala Val Ser Gly Trp Val Thr Asp Arg Arg Thr Ala  
 20 25 30  
 Val Asp Leu Arg Gly Arg Glu Val Glu Val Leu Gly Glu Val Pro  
 15 35 40 45  
 Ala Ala Gly Gly Ser Pro Leu Arg Gln Tyr Phe Phe Glu Thr Arg  
 50 55 60  
 Cys Lys Ala Asp Asn Ala Glu Glu Gly Gly Pro Gly Ala Gly Gly  
 20 65 70 75  
 Gly Gly Cys Arg Gly Val Asp Arg Arg His Trp Val Ser Glu Cys  
 80 85 90  
 His Ala Lys Gln Ser Tyr Val Arg Ala Leu Thr Ala Asp Ala Gln  
 25 95 100 105  
 Gly Arg Val Gly Trp Arg Trp Ile Arg Ile Asp Thr Ala Cys Val  
 30 110 115 120  
 Cys Thr Leu Leu Ser Arg Thr Gly Arg Ala  
 125 130

35

(2) INFORMATION FOR SEQ ID NO:61:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 130 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:

Gly Val Ser Glu Thr Ala Pro Ala Ser Arg Arg Gly Glu Leu Ala  
 45 1 5 10 15  
 Val Cys Asp Ala Val Ser Gly Trp Val Thr Asp Arg Arg Thr Ala  
 20 25 30  
 Val Asp Leu Arg Gly Arg Glu Val Glu Val Leu Gly Glu Val Pro  
 50 35 40 45  
 Ala Ala Gly Gly Ser Pro Leu Arg Gln Tyr Phe Phe Glu Thr Arg  
 55 50 55 60  
 Cys Lys Ala Asp Asn Ala Glu Glu Gly Gly Pro Gly Ala Gly Gly  
 60 65 70 75  
 Gly Gly Cys Arg Gly Val Asp Arg Arg His Trp Val Ser Glu Cys  
 80 85 90  
 Lys Ala Lys Gln Ser Tyr Val Arg Ala Leu Thr Ala Asp Ala Gln  
 95 100 105  
 Gly Arg Phe Gly Trp Arg Trp Ile Arg Ile Asp Thr Ala Cys Val  
 65 110 115 120  
 Cys Thr Leu Leu Ser Arg Thr Gly Arg Ala  
 125 130

-60-

## (2) INFORMATION FOR SEQ ID NO:62:

## (i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 130 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:

10 Gly Val Ser Glu Thr Ala Pro Ala Ser Arg Arg Gly Glu Leu Ala  
1 5 10 15  
Val Cys Asp Ala Val Ser Gly Trp Val Thr Asp Arg Arg Thr Ala  
20 25 30  
15 Val Asp Leu Arg Gly Arg Glu Val Glu Val Leu Gly Glu Val Pro  
35 40 45  
Ala Ala Gly Gly Ser Pro Leu Arg Gln Tyr Phe Phe Glu Thr Arg  
20 50 55 60  
Cys Lys Ala Asp Asn Ala Glu Glu Gly Gly Pro Gly Ala Gly Gly  
65 70 75  
25 Gly Gly Cys Arg Gly Val Asp Arg Gln His Trp Val Ser Glu Cys  
80 85 90  
Lys Ala Lys Gln Ser Tyr Val Arg Ala Leu Thr Ala Asp Ala Gln  
95 100 105  
30 Gly Arg Val Gly Trp Arg Trp Ile Arg Ile Asp Thr Ala Cys Val  
110 115 120  
Cys Thr Leu Leu Ser Arg Thr Gly Arg Ala  
35 125 130

## (2) INFORMATION FOR SEQ ID NO:63:

## (i) SEQUENCE CHARACTERISTICS:

- 40 (A) LENGTH: 130 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:

45 Gly Val Ser Glu Thr Ala Pro Ala Ser Arg Arg Gly Glu Leu Ala  
1 5 10 15  
Val Cys Asp Ala Val Ser Gly Trp Val Thr Asp Arg Arg Thr Ala  
50 20 25 30  
Val Asp Leu Arg Gly Arg Glu Val Glu Val Leu Gly Glu Val Pro  
35 40 45  
55 Ala Ala Gly Gly Ser Pro Leu Arg Gln Tyr Phe Phe Glu Thr Arg  
50 55 60  
Cys Lys Ala Asp Asn Ala Glu Glu Gly Gly Pro Gly Ala Gly Gly  
60 65 70 75  
Gly Gly Cys Arg Gly Val Asp Arg His His Trp Val Ser Glu Cys  
80 85 90  
Lys Ala Lys Gln Ser Tyr Val Arg Ala Leu Thr Ala Asp Ala Gln  
65 95 100 105  
Gly Arg Val Gly Trp Arg Trp Ile Arg Ile Asp Thr Ala Cys Val  
110 115 120

-61-

Cys Thr Leu Leu Ser Arg Thr Gly Arg Ala  
125 130

## (2) INFORMATION FOR SEQ ID NO:64:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 130 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:

Gly Val Ser Glu Thr Ala Pro Ala Ser Arg Arg Gly Glu Leu Ala  
1 5 10 15  
Val Cys Asp Ala Val Ser Gly Trp Val Thr Asp Arg Arg Thr Ala  
20 30  
Val Asp Leu Arg Gly Arg Glu Val Glu Val Leu Gly Glu Val Pro  
35 40 45  
Ala Ala Gly Gly Ser Pro Leu Arg Gln Tyr Phe Phe Glu Thr Arg  
50 55 60  
Cys Lys Ala Asp Asn Ala Glu Glu Gly Gly Pro Gly Ala Gly Gly  
65 70 75  
Gly Gly Cys Arg Gly Val Asp Arg Asn His Trp Val Ser Glu Cys  
80 85 90  
Lys Ala Lys Gln Ser Tyr Val Arg Ala Leu Thr Ala Asp Ala Gln  
95 100 105  
Gly Arg Val Gly Trp Arg Trp Ile Arg Ile Asp Thr Ala Cys Val  
110 115 120  
Cys Thr Leu Leu Ser Arg Thr Gly Arg Ala  
125 130

## (2) INFORMATION FOR SEQ ID NO:65:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 130 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:

Gly Val Ser Glu Thr Ala Pro Ala Ser Arg Arg Gly Glu Leu Ala  
1 5 10 15  
Val Cys Asp Ala Val Ser Gly Trp Val Thr Asp Arg Arg Thr Ala  
20 30  
Val Asp Leu Arg Gly Arg Glu Val Glu Val Leu Gly Glu Val Pro  
35 40 45  
Ala Ala Gly Gly Ser Pro Leu Arg Gln Tyr Phe Phe Glu Thr Arg  
50 55 60  
Cys Lys Ala Asp Asn Ala Glu Glu Gly Gly Pro Gly Ala Gly Gly  
65 70 75  
Gly Gly Cys Arg Gly Val Asp Arg Thr His Trp Val Ser Glu Cys  
80 85 90  
Lys Ala Lys Gln Ser Tyr Val Arg Ala Leu Thr Ala Asp Ala Gln  
95 100 105

-62-

Gly Arg Val Gly Trp Arg Trp Ile Arg Ile Asp Thr Ala Cys Val  
 110 115 120

5 Cys Thr Leu Leu Ser Arg Thr Gly Arg Ala  
 125 130

## (2) INFORMATION FOR SEQ ID NO:66:

- 10 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 130 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:

15 Gly Val Ser Glu Thr Ala Pro Ala Ser Arg Arg Gly Glu Leu Ala  
 1 5 10 15  
 20 Val Cys Asp Ala Val Ser Gly Trp Val Thr Asp Arg Arg Thr Ala  
 20 25 30  
 Val Asp Leu Arg Gly Arg Glu Val Glu Val Leu Gly Glu Val Pro  
 35 40 45  
 25 Ala Ala Gly Gly Ser Pro Leu Arg Gln Tyr Phe Phe Glu Thr Arg  
 50 55 60  
 Cys Lys Ala Asp Asn Ala Glu Glu Gly Gly Pro Gly Ala Gly Gly  
 65 70 75  
 30 Gly Gly Cys Arg Gly Val Asp Arg Tyr His Trp Val Ser Glu Cys  
 80 85 90  
 35 Lys Ala Lys Gln Ser Tyr Val Arg Ala Leu Thr Ala Asp Ala Gln  
 95 100 105  
 Gly Arg Val Gly Trp Arg Trp Ile Arg Ile Asp Thr Ala Cys Val  
 110 115 120  
 40 Cys Thr Leu Leu Ser Arg Thr Gly Arg Ala  
 125 130

## (2) INFORMATION FOR SEQ ID NO:67:

- 45 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 130 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:

50 Gly Val Ser Glu Thr Ala Pro Ala Ser Arg Arg Gly Glu Leu Ala  
 1 5 10 15  
 55 Val Cys Asp Ala Val Ser Gly Trp Val Thr Asp Arg Arg Thr Ala  
 20 25 30  
 Val Asp Leu Arg Gly Arg Glu Val Glu Val Leu Gly Glu Val Pro  
 35 40 45  
 60 Ala Ala Gly Gly Ser Pro Leu Arg Gln Tyr Phe Phe Glu Thr Arg  
 50 55 60  
 65 Cys Lys Ala Asp Asn Ala Glu Glu Gly Gly Pro Gly Ala Gly Gly  
 65 70 75  
 Gly Gly Cys Arg Gly Val Asp Arg Trp His Trp Val Ser Glu Cys  
 80 85 90

-63-

Lys Ala Lys Gln Ser Tyr Val Arg Ala Leu Thr Ala Asp Ala Gln  
 95 100 105  
 Gly Arg Val Gly Trp Arg Trp Ile Arg Ile Asp Thr Ala Cys Val  
 110 115 120  
 Cys Thr Leu Leu Ser Arg Thr Gly Arg Ala  
 125 130

5  
 10 (2) INFORMATION FOR SEQ ID NO:68:  
 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 130 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear  
 15  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:  
 20 Gly Val Ser Glu Thr Ala Pro Ala Ser Arg Arg Gly Glu Leu Ala  
 1 5 10 15  
 Val Cys Asp Ala Val Ser Gly Trp Val Thr Asp Arg Arg Thr Ala  
 20 25 30  
 25 Val Asp Leu Arg Gly Arg Glu Val Glu Val Leu Gly Glu Val Pro  
 35 40 45  
 Ala Ala Gly Gly Ser Pro Leu Arg Gln Tyr Phe Phe Glu Thr Arg  
 50 55 60  
 30 Cys Lys Ala Asp Asn Ala Glu Glu Gly Gly Pro Gly Ala Gly Gly  
 65 70 75  
 35 Gly Gly Cys Arg Gly Val Asp Arg Arg His Trp Val Ser Glu Cys  
 80 85 90  
 Lys Ala Lys Gln Ser Tyr Val Arg Ala Leu Thr Ala Asp Ala Gln  
 95 100 105  
 40 Gly Arg Val Gly Trp Arg Trp Ile Arg Ile Glu Thr Ala Cys Val  
 110 115 120  
 Cys Thr Leu Leu Ser Arg Thr Gly Arg Ala  
 125 130  
 45 (2) INFORMATION FOR SEQ ID NO:69:  
 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 130 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear  
 50  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:  
 55 Gly Val Ser Glu Thr Ala Pro Ala Ser Arg Arg Gly Glu Leu Ala  
 1 5 10 15  
 Val Cys Asp Ala Val Ser Gly Trp Val Thr Asp Arg Arg Thr Ala  
 20 25 30  
 60 Val Asp Leu Arg Gly Arg Glu Val Glu Val Leu Gly Glu Val Pro  
 35 40 45  
 Ala Ala Gly Gly Ser Pro Leu Arg Gln Tyr Phe Phe Glu Thr Arg  
 50 55 60  
 65 Cys Lys Ala Asp Asn Ala Glu Glu Gly Gly Pro Gly Ala Gly Gly  
 65 70 75

-64-

Gly Gly Cys Arg Gly Val Asp Arg Arg His Trp Val Ser Glu Cys  
80 85 90  
5 Lys Ala Lys Gln Ser Tyr Val Arg Ala Leu Thr Ala Asp Ala Gln  
95 100 105  
Gly Arg Val Gly Trp Arg Trp Ile Arg Ile Asn Thr Ala Cys Val  
110 115 120  
10 Cys Thr Leu Leu Ser Arg Thr Gly Arg Ala  
125 130

## (2) INFORMATION FOR SEQ ID NO:70:

- 15 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 130 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

## 20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:

Gly Val Ser Glu Thr Ala Pro Ala Ser Arg Arg Gly Glu Leu Ala  
1 5 10 15  
25 Val Cys Asp Ala Val Ser Gly Trp Val Thr Asp Arg Arg Thr Ala  
20 25 30  
Val Asp Leu Arg Gly Arg Glu Val Glu Val Leu Gly Glu Val Pro  
35 40 45  
30 Ala Ala Gly Gly Ser Pro Leu Arg Gln Tyr Phe Phe Glu Thr Arg  
50 55 60  
35 Cys Lys Ala Asp Asn Ala Glu Glu Gly Gly Pro Gly Ala Gly Gly  
65 70 75  
Gly Gly Cys Arg Gly Val Asp Arg Arg His Trp Val Ser Glu Cys  
80 85 90  
40 Lys Ala Lys Gln Ser Tyr Val Arg Ala Leu Thr Ala Asp Ala Gln  
95 100 105  
Gly Arg Val Gly Trp Arg Trp Ile Arg Ile Gln Thr Ala Cys Val  
110 115 120  
45 Cys Thr Leu Leu Ser Arg Thr Gly Arg Ala  
125 130

## (2) INFORMATION FOR SEQ ID NO:71:

- 50 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 130 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

## 55 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:

Gly Val Ser Glu Thr Ala Pro Ala Ser Arg Arg Gly Glu Leu Ala  
1 5 10 15  
60 Val Cys Asp Ala Val Ser Gly Trp Val Thr Asp Arg Arg Thr Ala  
20 25 30  
Val Asp Leu Arg Gly Arg Glu Val Glu Val Leu Gly Glu Val Pro  
35 40 45  
65 Ala Ala Gly Gly Ser Pro Leu Arg Gln Tyr Phe Phe Glu Thr Arg  
50 55 60

-65-

Cys Lys Ala Asp Asn Ala Glu Glu Gly Gly Pro Gly Ala Gly Gly  
 65 70 75  
 Gly Gly Cys Arg Gly Val Asp Arg Arg His Trp Val Ser Glu Cys  
 80 85 90  
 Lys Ala Lys Gln Ser Tyr Val Arg Ala Leu Thr Ala Asp Ala Gln  
 95 100 105  
 Gly Arg Val Gly Trp Arg Trp Ile Arg Ile Tyr Thr Ala Cys Val  
 110 115 120  
 Cys Thr Leu Leu Ser Arg Thr Gly Arg Ala  
 125 130

15 (2) INFORMATION FOR SEQ ID NO:72:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 130 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:

Gly Val Ser Glu Thr Ala Pro Ala Ser Arg Arg Gly Glu Leu Ala  
 1 5 10 15  
 Val Cys Asp Ala Val Ser Gly Trp Val Thr Asp Arg Arg Thr Ala  
 20 25 30  
 Val Asp Leu Arg Gly Arg Glu Val Glu Val Leu Gly Glu Val Pro  
 35 40 45  
 Ala Ala Gly Gly Ser Pro Leu Arg Gln Tyr Phe Phe Glu Thr Arg  
 50 55 60  
 Cys Lys Ala Asp Asn Ala Glu Glu Gly Gly Pro Gly Ala Gly Gly  
 65 70 75  
 Gly Gly Cys Arg Gly Val Asp Arg Arg His Trp Val Ser Glu Cys  
 80 85 90  
 Lys Ala Lys Gln Ser Tyr Val Arg Ala Leu Thr Ala Asp Ala Gln  
 95 100 105  
 Gly Arg Val Gly Trp Arg Trp Ile Arg Ile Ser Thr Ala Cys Val  
 110 115 120  
 Cys Thr Leu Leu Ser Arg Thr Gly Arg Ala  
 125 130

(2) INFORMATION FOR SEQ ID NO:73:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 130 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:

Gly Val Ser Glu Thr Ala Pro Ala Ser Arg Arg Gly Glu Leu Ala  
 1 5 10 15  
 Val Cys Asp Ala Val Ser Gly Trp Val Thr Asp Arg Arg Thr Ala  
 20 25 30  
 Val Asp Leu Arg Gly Arg Glu Val Glu Val Leu Gly Glu Val Pro  
 35 40 45

-66-

Ala Ala Gly Gly Ser<sup>1</sup> Pro Leu Arg Gln Tyr Phe Phe Glu Thr Arg  
50 55 60

5 Cys Lys Ala Asp Asn<sup>65</sup> Ala Glu Glu Gly Gly<sup>70</sup> Pro Gly Ala Gly Gly<sup>75</sup>

Gly Gly Cys Arg Gly<sup>80</sup> Val Asp Arg Arg His<sup>85</sup> Trp Val Ser Glu Cys<sup>90</sup>

10 Lys Ala Lys Gln Ser<sup>95</sup> Tyr Val Arg Ala Leu<sup>100</sup> Thr Ala Asp Ala Gln<sup>105</sup>

Gly Arg Val Gly<sup>110</sup> Trp Arg Trp Ile Arg Ile<sup>115</sup> Thr Thr Ala Cys Val<sup>120</sup>

15 Cys Thr Leu Leu Ser<sup>125</sup> Arg Thr Gly Arg Ala<sup>130</sup>

## (2) INFORMATION FOR SEQ ID NO:74:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 4 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:

Ile Lys Thr Gly  
1 4

## (2) INFORMATION FOR SEQ ID NO:75:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 5 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:

Glu Ile Lys Thr Gly  
1 5

## (2) INFORMATION FOR SEQ ID NO:76:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 6 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:

Glu Ile Lys Thr Gly Asn  
1 5 6

## (2) INFORMATION FOR SEQ ID NO:77:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 4 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:

Ser Pro Val Lys  
1 4

## (2) INFORMATION FOR SEQ ID NO:78:

- (i) SEQUENCE CHARACTERISTICS:



-67-

- (A) LENGTH: 4 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:78:

Lys Ser Ser Ala  
1 4

10 (2) INFORMATION FOR SEQ ID NO:79:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 6 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:79:

20 Tyr Ala Glu His Lys Ser  
1 5 6

(2) INFORMATION FOR SEQ ID NO:80:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 7 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:80:

30

Arg Tyr Ala Glu His Lys Ser  
1 5 7

(2) INFORMATION FOR SEQ ID NO:81:

35

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 8 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:

Arg Tyr Ala Glu His Lys Ser His  
1 5 8

45

(2) INFORMATION FOR SEQ ID NO:82:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 7 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:82:

55 Tyr Ala Glu His Lys Ser His  
1 5 7

(2) INFORMATION FOR SEQ ID NO:83:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 5 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear

60

65 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:83:

Ala Asn Arg Thr Ser  
1 5

-68-

## (2) INFORMATION FOR SEQ ID NO:84:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 4 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:84:

Ala Asn Arg Thr  
1 4

## (2) INFORMATION FOR SEQ ID NO:85:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 4 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:85:

Asn Arg Thr Ser  
1 4

## (2) INFORMATION FOR SEQ ID NO:86:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 4 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:86:

Lys Glu Ala Arg  
1 4

## (2) INFORMATION FOR SEQ ID NO:87:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 5 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:87:

Lys Glu Ala Arg Pro  
1 5

## (2) INFORMATION FOR SEQ ID NO:88:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 4 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:88:

Ile Asp Asp Lys  
1 4

## (2) INFORMATION FOR SEQ ID NO:89:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 4 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:89:

-69-

Ser Glu Asn Asn  
1 4

5 (2) INFORMATION FOR SEQ ID NO:90:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 5 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:90:

Thr Ser Glu Asn Asn  
1 5

15 (2) INFORMATION FOR SEQ ID NO:91:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 6 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:91:

25 Thr Ser Glu Asn Asn Lys  
1 5 6

(2) INFORMATION FOR SEQ ID NO:92:

30 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 4 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:92:

Lys Leu Val Gly  
1 4

40 (2) INFORMATION FOR SEQ ID NO:93:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 47 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:93:

50 Cys Cys Gly Cys Gly Cys Gly Cys Thr Cys Thr Ala Gly Ala Gly  
1 5 10 15

Thr Cys Gly Ala Cys Ala Ala Gly Cys Ala Gly Thr Ala Cys Thr  
20 25 30

55 Thr Cys Thr Ala Th Gly Ala Gly Ala Cys Gly Ala Ala Gly Thr  
35 40 45

Gly Thr  
47

60 (2) INFORMATION FOR SEQ ID NO:94:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 47 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

65 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:94:

-70-

Cys Cys Gly Cys Gly Cys Gly Cys Thr Cys Thr Ala Gly Ala Gly  
 1 5 10 15  
 5 Thr Cys Gly Ala Cys Ala Ala Ala Cys Ala Ala Thr Ala Thr Thr  
 20 25 30  
 Thr Thr Thr Thr Cys Gly Ala Ala Ala Cys Cys Cys Gly Ala Thr  
 35 40 45  
 10 Gly Cys  
 47

## (2) INFORMATION FOR SEQ ID NO:95:

15 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 47 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

## 20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:95:

Cys Cys Gly Cys Gly Cys Gly Cys Thr Cys Thr Ala Gly Ala Gly  
 1 5 10 15  
 25 Thr Cys Gly Ala Cys Ala Ala Gly Cys Ala Gly Thr Ala Cys Thr  
 20 25 30  
 Thr Cys Thr Ala Thr Gly Ala Gly Ala Cys Thr Ala Ala Gly Thr  
 35 40 45  
 30 Gly Thr  
 47

## 35 (2) INFORMATION FOR SEQ ID NO:96:

35 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 47 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

## 40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:96:

Cys Cys Gly Cys Gly Cys Gly Cys Thr Cys Thr Ala Gly Ala Gly  
 1 5 10 15  
 45 Thr Cys Gly Ala Cys Ala Ala Gly Cys Ala Gly Thr Ala Cys Thr  
 20 25 30  
 Thr Cys Thr Ala Thr Gly Ala Gly Ala Cys Ala Ala Ala Gly Thr  
 35 40 45  
 50 Gly Thr  
 47

## 55 (2) INFORMATION FOR SEQ ID NO:97:

55 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 45 amino acids  
 (B) TYPE: amino acid  
 60 (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:97:

65 Cys Gly Gly Cys Thr Cys Ala Gly Gly Gly Cys Cys Gly Ala Ala  
 1 5 10 15  
 Thr Thr Cys Gly Cys Ala Cys Ala Cys Gly Cys Ala Gly Gly Ala  
 20 25 30

5 (2) INFORMATION FOR SEQ ID NO:98:

10

15 Cys Gly Gly Cys Thr Cys Ala Gly Gly Gly Cys Cys Gly Ala Ala  
1 5 10 15

20 Gly Gly Thr Gly Thr Cys Ala Ala Thr Thr Cys Gly Gly Ala Thr  
35 45

25

30

Cys Gly Gly Cys Thr Cys Ala Gly Gly Gly Cys Cys Gly Ala Ala  
1 5 10 15

40 35 40 45

45

50

Cys Gly Gly Cys Thr Cys Ala Gly Gly Gly Cys Cys Gly Ala Ala  
1 5 10 15

Thr Gly Thr Ala Thr Cys Gly Ala Thr Gly Cys Thr Ala Ala Thr  
35 40 45

Claims

1. An isolated nucleic acid encoding NT-4.
2. An isolated nucleic acid of claim 1 comprising the nucleotide sequence shown in Figure 1 for mature human NT-4.
- 5 3. A vector comprising the nucleic acid of claim 1.
4. A host cell comprising the nucleic acid of claim 1.
5. A composition comprising NT-4 from an animal species, which composition is free of contaminating polypeptides of that animal species.
6. A composition of claim 5 wherein the NT-4 is from human.
- 10 7. A nucleic acid that hybridizes to DNA encoding NT-4 under stringent conditions, excluding nucleic acid encoding NGF, BDNF, or NT-3.
8. A nucleic acid of claim 7 comprising the nucleotide sequence shown in Figure 3 for human NT-4 $\beta$ .
9. A nucleic acid of claim 7 comprising the nucleotide sequence shown in Figure 15 4 for human NT-4 $\gamma$ .
10. A nucleic acid of claim 7 comprising the nucleotide sequence shown in Figure 5 for human NT-4 $\Delta$ .
11. A composition comprising NT-4 linked to an immunogenic polypeptide or a non-proteinaceous polymer.
- 20 12. A pharmaceutical composition comprising an effective amount of NT-4 in a pharmaceutically acceptable carrier.
13. A composition of claim 12 further comprising NGF, BDNF, or NT-3.
14. An antibody that is capable of binding NT-4, but that is not capable of binding NGF, BDNF, or NT-3.
- 25 15. A monoclonal antibody capable of binding NT-4.
16. A monoclonal antibody of claim 15 which does not cross-react with NGF, BDNF, or NT-3.
17. A method for treating a neurodegenerative disease or damaged nerve cells comprising administering to a mammal an effective amount of NT-4.
- 30 18. A method of claim 17 wherein the mammal is human.
19. A method of claim 17 wherein an effective amount of NGF, BDNF, or NT-3 is also administered to the mammal.
20. A method of claim 17 wherein the neurodegenerative disease is Huntington's chorea, Alzheimer's disease, ALS, or Parkinson's disease and the damaged nerve cells are due to trauma.
- 35 21. A method for detecting NT-4 in vitro or in vivo comprising employing an antibody of claim 14.
22. A method for purifying NT-4 comprising passing a mixture of NT-4 over a column to which is bound an antibody of claim 14.

23. A method for producing NT-4, comprising culturing the host cell of claim 4 and recovering NT-4 from the host cell culture.

24. The method of claim 23 wherein the NT-4 is recovered from the host cell culture medium.

ATG CTC CCT CTC CCC TCA TGC TCC CTC CCC ATC CTC CTC CTT TTC  
Met Leu Pro Leu Pro Ser Cys Ser Leu Pro Ile Leu Leu Leu Phe

CTC CTC CCC AGT GTG CCA ATT GAG TCC CAA CCC CCA CCC TCA ACA TTG  
Leu Leu Pro Ser Val Pro Ile Glu Ser Gln Pro Pro Pro Ser Thr Leu

CCC CCT TTT CTG GCC CCT GAG TGG GAC CTT CTC TCC CCC CGA GTA GTC  
Pro Pro Phe Leu Ala Pro Glu Trp Asp Leu Leu Ser Pro Arg Val Val  
\*

CTG TCT AGG GGT GCC CCT GCT GGG CCC CCT CTG CTC TTC CTG CTG GAG  
Leu Ser Arg Gly Ala Pro Ala Gly Pro Pro Leu Leu Phe Leu Leu Glu

GCT GGG GCC TTT CGG GAG TCA GCA GGT GCC CCG GCC AAC CGC AGC CGG  
Ala Gly Ala Phe Arg Glu Ser Ala Gly Ala Pro Ala Asn Arg Ser Arg

↓

CGT GGG GTG AGC GAA ACT GCA CCA GCG AGT CGT CGG GGT GAG CTG GCT  
Arg Gly Val Ser Glu Thr Ala Pro Ala Ser Arg Arg Gly Glu Leu Ala  
1 10

GTG TGC GAT GCA GTC AGT GGC TGG GTG ACA GAC CGC CGG ACC GCT GTG  
Val Cys Asp Ala Val Ser Gly Trp Val Thr Asp Arg Arg Thr Ala Val  
20 30

GAC TTG CGT GGG CGC GAG GTG GAG GTG TTG GGC GAG GTG CCT GCA GCT  
Asp Leu Arg Gly Arg Glu Val Glu Val Leu Gly Glu Val Pro Ala Ala  
40

GGC GGC AGT CCC CTC CGC CAG TAC TTC TTT GAA ACC CGC TGC AAG GCT  
Gly Gly Ser Pro Leu Arg Gln Tyr Phe Phe Glu Thr Arg Cys Lys Ala  
50 60

GAT AAC GCT GAG GAA GGT GGC CCG GGG GCA GGT GGA GGG GGC TGC CGG  
Asp Asn Ala Glu Glu Gly Gly Pro Gly Ala Gly Gly Gly Gly Cys Arg  
70

GGA GTG GAC AGG AGG CAC TGG GTA TCT GAG TGC AAG GCC AAG CAG TCC  
Gly Val Asp Arg Arg His Trp Val Ser Glu Cys Lys Ala Lys Gln Ser  
80 90

TAT GTG CGG GCA TTG ACC GCT GAT GCC CAG GGC CGT GTG GGC TGG CGA  
Tyr Val Arg Ala Leu Thr Ala Asp Ala Gln Gly Arg Val Gly Trp Arg  
100 110

TGG ATT CGA ATT GAC ACT GCC TGC GTC TGC ACA CTC CTC AGC CGG ACT  
Trp Ile Arg Ile Asp Thr Ala Cys Val Cys Thr Leu Leu Ser Arg Thr  
120

GGC CGG GCC TGA G  
Gly Arg Ala OP\*  
130



[illegible]

FIGURE 3

```

1 C   GAG AGA TGC TCT GAG AGA TGC TCC CAC TCC CCC AGG CTC CCT CCG
1     Glu Arg Cys Ser Glu Arg Cys Ser His Ser Pro Arg Leu Pro Pro

47 CAT CCC CCT CAT TTT CCT CCT CCC CAG TGT GTC AAT GGA GTC CTA ACC
16 His Pro Pro His Phe Pro Pro Pro Gln Cys Val Asn Gly Val Leu Thr

95 CCA TCC TCG ACA TTG TCG CCT TTT CCT CCT CCA GAG TGG GAC CTT CTT
32 Pro Ser Ser Thr Leu Ser Pro Phe Pro Pro Pro Glu Trp Asp Leu Leu

143 TTC CCC CGA GTG GTC CTG TCT AGG GGT GCC GCT GCC GGG CCC CCT CTG
48 Phe Pro Arg Val Val Leu Ser Arg Gly Ala Ala Ala Gly Pro Pro Leu

191 GTC TTC CTG CTG GAG ACT GGA GCC TTT CGG GAG TCA GCA GGC GCC CGG
64 Val Phe Leu Leu Glu Thr Gly Ala Phe Arg Glu Ser Ala Gly Ala Arg

239 GCC AAC CGC AGC CAG CGA GGG GTG AGC GAT ACT TCA CCG GCG AGT CAT
80 Ala Asn Arg Ser Gln Arg Gly Val Ser Asp Thr Ser Pro Ala Ser His

287 CAG GGT GAG CTG GCC GTG TGC GAT GCA GTC AGT GTC TGG GTG ACA GAC
96 Gln Gly Glu Leu Ala Val Cys Asp Ala Val Ser Val Trp Val Thr Asp

335 CCC TGG ACT GCT GTG GAC TTG GGT GTG CTC GAG GTG GAG GTG TTG GGC
112 Pro Trp Thr Ala Val Asp Leu Gly Val Leu Glu Val Glu Val Leu Gly

383 GAG GTG CCT GCA GCT GTC GGC AGT TCC CTC CGC CAG CAC TTC TTT GTT
128 Glu Val Pro Ala Ala Val Gly Ser Ser Leu Arg Gln His Phe Phe Val

431 GCC CGC TTC GAG GCC GAT AAA TCT GAG GAA GGT GGC CCG GGG GTA GGT
144 Ala Arg Phe Glu Ala Asp Lys Ser Glu Glu Gly Gly Pro Gly Val Gly

479 GGA GGG GCT GCC GCC GGG GTG TGG ACC GGG GGG CAC TGG GTG TCT GAG
160 Gly Gly Ala Ala Ala Gly Val Trp Thr Gly Gly His Trp Val Ser Glu

527 TGC AAG GCC AAG CAG TCC TAT GTG CGG GCA TTG ACC GCT GAT GCC CAG
176 Cys Lys Ala Lys Gln Ser Tyr Val Arg Ala Leu Thr Ala Asp Ala Gln

575 GGC CGT GTG GAC TGG CGA TGG ATT CAA ATT GGC ACA GCC TGT GTC TGC
192 Gly Arg Val Asp Trp Arg Trp Ile Gln Ile Gly Thr Ala Cys Val Cys

623 ACA CTC CTC AGC CGG ACT GGC CGG GCC TGA GACTTATA CCCAGGAACT
208 Thr Leu Leu Ser Arg Thr Gly Arg Ala OP*

671 GGTGAGGCAG AAAAA

```

1 ACTGGAGCGC AGCACCACGC CCAGCTAATT TTGGTATTAT CAGTAGAGAT GTTGTTCAC  
61 AGTGTGGCC AGGCTGCTCT CAAACTCCTG ACCTCAAGTC AAACACCCGC CTCAGCCTCC  
121 CAAAGTGCTG GGA CTACAGG TGTGAGCCAT AGTGCCTGAC CTGTAGTTGT TGAATATTTA  
181 TTATTAATCT ACAAGTTGGG TGTGATGCAA GTCCTTTATA TGGAGTCCCC CAAACTTCTA  
241 G AGC AAG GGC TTC CCC ATA ATC CTG GCA GGC AGG CCT CCC CTG GGG TTC  
1 Ser Lys Gly Phe Pro Ile Ile Leu Ala Gly Arg Pro Pro Leu Gly Phe  
290 CCA ACT TCT GAC CCC ACT GAA GTG TTT ATC TTC TTC CCT AAT CCC AGC CTC  
17 Pro Thr Ser Asp Pro Thr Glu Val Phe Ile Phe Phe Pro Asn Pro Ser Leu  
341 CTT TTC CCT GTC TCC ATG TGC TCT GAG AGA TGC TCT GAG AGA TGC TCC TGC  
34 Leu Phe Pro Val Ser Met Cys Ser Glu Arg Cys Ser Glu Arg Cys Ser Cys  
392 TCC CCC AGG CTC CCT CCG CAT CCC CCT CAT TTT CCT CCT CCC CAG TGT GTC  
51 Ser Pro Arg Leu Pro Pro His Pro Pro His Phe Pro Pro Pro Gln Cys Val  
443 ATT GGA GTC CTA ACC CCA TCC TCG ACA TTG TCG CGT TTT CCT CCT CCA GAG  
68 Ile Gly Val Leu Thr Pro Ser Ser Thr Leu Ser Arg Phe Pro Pro Pro Glu  
494 TGG GAC CTT CTT TTC CCC CGA GTG GTC CTG TCT AGG GGT GCC GCT GCC GGG  
85 Trp Asp Leu Leu Phe Pro Arg Val Val Leu Ser Arg Gly Ala Ala Ala Gly  
545 CCC CCT CTG GTC TTC CTG CTG GAG ACT GGA GCC TTT CGG GAG TCA GCA GGC  
102 Pro Pro Leu Val Phe Leu Leu Glu Thr Gly Ala Phe Arg Glu Ser Ala Gly  
596 GCC CGG GCC AAC CGC AGC CAG CGT GGG GTG AGC GAT ACT TCA CCG GTG AGT  
119 Ala Arg Ala Asn Arg Ser Gln Arg Gly Val Ser Asp Thr Ser Pro Val Ser  
647 CAT CAG GGT GAG CTG GCC GTG TGC GAT GCA GTC ACT GTC TGG GTG ACA GAC  
136 His Gln Gly Glu Leu Ala Val Cys Asp Ala Val Thr Val Trp Val Thr Asp  
698 CCC TGG ACT GCT GTG GAC TTG GGT GTG CTC GAG GTG GAG GTG TTG GGT GAG  
153 Pro Trp Thr Ala Val Asp Leu Gly Val Leu Glu Val Glu Val Leu Gly Glu  
749 GTG CCT GCA GCT GGC AGC AGT TCC CTC CGC CAG CAC TTC TTT GTT ACC CGC  
170 Val Pro Ala Ala Gly Ser Ser Ser Leu Arg Gln His Phe Phe Val Thr Arg  
800 TTC GAG GCC GAT AAA TCT AAG GAA GGT GGC CCG GGG GTA GGT GGA GGA CCT  
187 Phe Glu Ala Asp Lys Ser Lys Glu Gly Gly Pro Gly Val Gly Gly Gly Pro  
851 GCC GCC GGG GTG TGG ACC GGG GGG CAC TGG GTG TCT GAG TGC AAG GCC AAG  
204 Ala Ala Gly Val Trp Thr Gly Gly His Trp Val Ser Glu Cys Lys Ala Lys  
902 CAG TCC TAT GGG CGG GCA TTG ACC ACT GAT GCC CAG GGC CGT GTG GAC TGG  
221 Gln Ser Tyr Gly Arg Ala Leu Thr Thr Asp Ala Gln Gly Arg Val Asp Trp  
953 CGA TGG ATT CAA ATT GGC ACT GCC TGT GTC TGC ACA CTC CTC AGC CGG ACT  
238 Arg Trp Ile Gln Ile Gly Thr Ala Cys Val Cys Thr Leu Leu Ser Arg Thr  
1004 GGC CGG GCC TGA GACTT ATACCCAGGA ACTGGTCAGG CAGAAAAAGA ACAGAGCTGG  
255 Gly Arg Ala OP\*  
1061 ATGCTGAGAG ACCTCAGGGT TGGCCAGCT GCTCTACGGA CGGACCCAG TTGGGGA  
1121 CATCAAATCA TCGCAAATC TCAACTGTCT GAATTTGAGC TCAATCTCTG TAGGATGGGT  
1181 GCAACAATGT

## FIGURE 5




1 TTTGAACTCC TGACCTCAAG TCAAACACCG CCTCAGCCTC CCAAAGTGCT GGGACCACAG  
61 GTGTGAGCCA TAGTGCCTGA CCTGTAGTTG TTGAATATTT ATTATTAATC TACAAGTTGG  
121 GTGTGATGCA AGTCCCATAC ATGGAGTCCC CCAAACCTTCT AGAGCAAGGG CTCCCCATA  
181 ATCCTGGCAG GCAGGCCTCC CCTGGGGTTC CCAACTTCTG ACCTCACTGA AGTGTTTATC  
241 CTCTTCTCTA ATCCCAGCCT CCTTTTCCCT GTTTCATGT CCTCTGAGAG ATGCTCCCGC  
301 TCCCCAGGC TCCCTCTGCA TCCCCCTCAT TTGCTTCCTC CCCAGTGTGT CAATGGAGTC  
361 CTAA CCC CCA CCC TTG ACA TTG TCC CCT TTT CCT CCT CCA GAG TGG  
1 Pro Pro Pro Leu Thr Leu Ser Pro Phe Pro Pro Pro Glu Trp  
407 GAC CTT ATT TTC CCC CAA GTG GTC CTG TCT AGG GGT GCC GCT GCC GGG  
15 Asp Leu Ile Phe Pro Gln Val Val Leu Ser Arg Gly Ala Ala Ala Gly  
455 CCC CCT CTG GTC TTC CTG CTG GAG ACT GGG GCC TTT TGG GAG TCA GCA  
31 Pro Pro Leu Val Phe Leu Leu Glu Thr Gly Ala Phe Trp Glu Ser Ala  
503 GGC ACC CGG GCC AAC CGC AGC CAG CGA GGG GTG AGC GAT ACT TCA CCG  
47 Gly Thr Arg Ala Asn Arg Ser Gln Arg Gly Val Ser Asp Thr Ser Pro  
551 GCG AGT CAT CAG GGT GAG CTG GCC GTG TGC GAT GCA GTC AGT GTC TGG  
63 Ala Ser His Gln Gly Glu Leu Ala Val Cys Asp Ala Val Ser Val Trp  
599 GTG ACA GAC CCC CGG ACC GCT GTG GAC TTG GTT GTG CTC GAG GTG GAG  
79 Val Thr Asp Pro Arg Thr Ala Val Asp Leu Val Val Leu Glu Val Glu  
647 GTG TTG GGT GAG GTG CCT GCA GCT GGC AGC AGT TCC CTC CAC CAA CAC  
95 Val Leu Gly Glu Val Pro Ala Ala Gly Ser Ser Ser Leu His Gln His  
695 TTC TTT GTC ACC TGC TTC AAG GCC GAT AAC TCT GAA GAA GGT GGC CCA  
111 Phe Phe Val Thr Cys Phe Lys Ala Asp Asn Ser Glu Glu Gly Gly Pro  
743 GGG GTA GGT GGA GGG GCT GCC GCT GGG GTG TGG ACC GGG GGG CAC TGG  
127 Gly Val Gly Gly Gly Ala Ala Ala Gly Val Trp Thr Gly Gly His Trp  
791 GTG TCT GAG TGC AAG GCC AAG CAG TCC TAT GTG CGG GCA TTG ACC GCT  
143 Val Ser Glu Cys Lys Ala Lys Gln Ser Tyr Val Arg Ala Leu Thr Ala  
839 GAT GCC CAG GGC CGT GTG GAC TGG CGA TGG ATT CAA ACT GGC ACA GCC  
159 Asp Ala Gln Gly Arg Val Asp Trp Arg Trp Ile Gln Thr Gly Thr Ala  
887 TGT GTC TGC ACA CTC CTC AGC CGG ACT GGC CGG GCC TGA GACTT  
175 Cys Val Cys Thr Leu Leu Ser Arg Thr Gly Arg Ala OP\*  
931 ATACCCAGGA ACTGGTCAGG CAGAAAAAGA ACAGAGCTAG G



# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 91/06950

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (If several classification symbols apply, indicate all) <sup>6</sup> According to International Patent Classification (IPC) or to both National Classification and IPC Int. Cl. 5      C 12 N 15/12      C 12 Q 1/68      C 12 P 21/08 A 61 K 37/02														
<b>II. FIELDS SEARCHED</b> <div style="text-align: center; border: 1px solid black; padding: 2px;">Minimum Documentation Searched<sup>7</sup></div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 30%; border: 1px solid black; padding: 2px;">Classification System</th> <th style="border: 1px solid black; padding: 2px;">Classification Symbols</th> </tr> <tr> <td style="border: 1px solid black; padding: 2px;">Int. Cl. 5</td> <td style="border: 1px solid black; padding: 2px;"> <div style="display: flex; justify-content: space-between;"> <span>C 12 N A 61 K</span> <span>C 12 P C 12 Q</span> <span>C 07 K G 01 N</span> </div> </td> </tr> </table> <div style="text-align: center; border: 1px solid black; padding: 2px;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched<sup>8</sup></div>			Classification System	Classification Symbols	Int. Cl. 5	<div style="display: flex; justify-content: space-between;"> <span>C 12 N A 61 K</span> <span>C 12 P C 12 Q</span> <span>C 07 K G 01 N</span> </div>								
Classification System	Classification Symbols													
Int. Cl. 5	<div style="display: flex; justify-content: space-between;"> <span>C 12 N A 61 K</span> <span>C 12 P C 12 Q</span> <span>C 07 K G 01 N</span> </div>													
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%; border: 1px solid black; padding: 2px;">Category<sup>o</sup></th> <th style="border: 1px solid black; padding: 2px;">Citation of Document,<sup>11</sup> with indication, where appropriate, of the relevant passages<sup>12</sup></th> <th style="width: 10%; border: 1px solid black; padding: 2px;">Relevant to Claim No.<sup>13</sup></th> </tr> <tr> <td style="border: 1px solid black; text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="border: 1px solid black; padding: 5px;">Neuron, volume 4, May 1990, Cell Press; A. Rosenthal et al.: "Primary structure and biological activity of a novel human neurotrophic factor", pages 767-773, see the whole document (cited in the application) -----</td> <td style="border: 1px solid black; text-align: center; vertical-align: top; padding: 5px;">1-10</td> </tr> <tr> <td style="border: 1px solid black; text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="border: 1px solid black; padding: 5px;">US, A, 4699875 (APPEL, S.H.) 13 October 1987, see the whole document -----</td> <td style="border: 1px solid black; text-align: center; vertical-align: top; padding: 5px;">17-20</td> </tr> <tr> <td style="border: 1px solid black; text-align: center; vertical-align: top; padding: 5px;">P, X</td> <td style="border: 1px solid black; padding: 5px;">Neuron, volume 6, no. 5, May 1991, Cell Press; F. Hallböök et al.: "Evolutionary studies of the nerve growth factor family reveal a novel member abundantly expressed in xenopus ovary", pages 845-858, see the whole article -----</td> <td style="border: 1px solid black; text-align: center; vertical-align: top; padding: 5px;">1, 3-5, 7, 23-24</td> </tr> </table>			Category <sup>o</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>	A	Neuron, volume 4, May 1990, Cell Press; A. Rosenthal et al.: "Primary structure and biological activity of a novel human neurotrophic factor", pages 767-773, see the whole document (cited in the application) -----	1-10	A	US, A, 4699875 (APPEL, S.H.) 13 October 1987, see the whole document -----	17-20	P, X	Neuron, volume 6, no. 5, May 1991, Cell Press; F. Hallböök et al.: "Evolutionary studies of the nerve growth factor family reveal a novel member abundantly expressed in xenopus ovary", pages 845-858, see the whole article -----	1, 3-5, 7, 23-24
Category <sup>o</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>												
A	Neuron, volume 4, May 1990, Cell Press; A. Rosenthal et al.: "Primary structure and biological activity of a novel human neurotrophic factor", pages 767-773, see the whole document (cited in the application) -----	1-10												
A	US, A, 4699875 (APPEL, S.H.) 13 October 1987, see the whole document -----	17-20												
P, X	Neuron, volume 6, no. 5, May 1991, Cell Press; F. Hallböök et al.: "Evolutionary studies of the nerve growth factor family reveal a novel member abundantly expressed in xenopus ovary", pages 845-858, see the whole article -----	1, 3-5, 7, 23-24												
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p><sup>o</sup> Special categories of cited documents: <sup>10</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p> </div> </div>														
<b>IV. CERTIFICATION</b> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border: 1px solid black; padding: 5px;">           Date of the Actual Completion of the International Search  <div style="text-align: center;">16-01-1992</div> </td> <td style="width: 50%; border: 1px solid black; padding: 5px;">           Date of Mailing of this International Search Report  <div style="text-align: center;">05 FEB 1992</div> </td> </tr> <tr> <td style="border: 1px solid black; padding: 5px;">           International Searching Authority  <div style="text-align: center;">EUROPEAN PATENT OFFICE</div> </td> <td style="border: 1px solid black; padding: 5px;">           Signature of Authorized Officer  <div style="text-align: center;">               MISS T. TAZELAAR           </div> </td> </tr> </table>			Date of the Actual Completion of the International Search <div style="text-align: center;">16-01-1992</div>	Date of Mailing of this International Search Report <div style="text-align: center;">05 FEB 1992</div>	International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center;">               MISS T. TAZELAAR           </div>								
Date of the Actual Completion of the International Search <div style="text-align: center;">16-01-1992</div>	Date of Mailing of this International Search Report <div style="text-align: center;">05 FEB 1992</div>													
International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center;">               MISS T. TAZELAAR           </div>													

Form PCT/ISA/210 (second sheet) (January 1985)

## FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATION WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE <sup>1</sup>

This International search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claim numbers \_\_\_\_\_ Authority, namely: \_\_\_\_\_ because they relate to subject matter not required to be searched by this  
 Remark: Although claims 17-20 are directed to a method of treatment of (diagnostic method practised on) the human/ animal body the search has been carried out on the alleged effects of the compound/composition."
2. ☐ Claim numbers \_\_\_\_\_ because they relate to parts of the International application that do not comply with the prescribed requirements to such an extent that no meaningful International search can be carried out, specifically:
3. ☐ Claim numbers \_\_\_\_\_ because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING <sup>2</sup>

This International Searching Authority found multiple inventions in this International application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International search report covers all searchable claims of the International application
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the International application for which fees were paid, specifically claims: \_\_\_\_\_
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers: \_\_\_\_\_
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

## Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

US 9106950  
SA 52616

EPO FORM P0479

BNSDOCID: <WO\_\_9205254A1\_I\_>